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Overweight and related co-morbidities 
Globally, the prevalence of overweight and obesity is increasing rapidly, and in 2016, 
39% of the total population was overweight and 13% obese [1]. According to the WHO, 
overweight is defined as a BMI >25 kg/m2 and obesity as a BMI >30 kg/m2 [1]. 
Overweight and obesity are often caused by an unhealthy lifestyle, with excessive energy 
intake, poor nutrient composition, and physical inactivity quickly creating a positive 
energy balance promoting weight gain [1]. Excess body weight has been, next to age, 
categorized as a major contributing factor for the development of non-communicable 
diseases such as cardiovascular disease (CVD) and type II diabetes mellitus (T2DM) [2] 
through a cascade of metabolic and inflammatory processes. Pro-inflammatory 
cytokines and other bioactive mediators are released by adipose tissue, negatively 
affecting blood lipid concentrations, adhesion molecules, coagulation, endothelial 
function, atherosclerosis, and insulin resistance [3].  
Energy intake regulation 
Chronic intake of excess energy causes a positive energy balance and weight gain in the 
longer term. Therefore, careful regulation of energy intake is of importance. However, 
dieting, weight loss, or long-term weight maintenance remain challenging as limited 
energy intake affects energy expenditure and often results in increased hunger 
sensation and desire to eat [4]. As fat mass and fat-free mass (FFM) decrease with weight 
loss, the total energy requirement is reduced, which often mitigates the negative energy 
balance caused by the limited energy intake. This indicates the importance of finding 
strategies to reduce energy intake next to simple caloric reduction. In this context, high-
protein diets may help to counteract the loss of FFM while simultaneously affecting 
appetite sensation.  
For appetite regulation, multiple pathways have been suggested to be acutely affected 
by high-protein diets, such as satiety-related anorexigenic gut peptides (e.g., GLP-1 and 
PYY), increased serum amino acid concentrations, and elevated diet-induced thermo-
genesis [4]. Other endogenous compounds suggested to be involved in energy intake 
regulation are the endocannabinoids [5]. 
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Endocannabinoids 
The endocannabinoid system (ECS) has been suggested to be involved in metabolic and 
cardiovascular health by influencing body composition, blood pressure (BP) regulation, 
and vasoactive properties [6-9]. The ECS is a complex system getting more and more 
interest lately. It consists of receptors (cannabinoid receptors 1 and 2), endogenous 
ligands, and enzymes ensuring synthesis and degradation of those ligands. The ligands 
are called endocannabinoids (e.g., anandamide (AEA) and 2-arachidonoylglycerol (2-
AG)) and endocannabinoid-related compounds (e.g., oleoylethanolamide (OEA), pal-
mitoylethanolamide (PEA), and pregnenolone (PREG)). Especially AEA and 2-AG have 
been suggested to exert blood pressure, vasoactive modifying properties, affect body 
composition, and metabolic markers such as blood lipoprotein concentrations and 
glucose metabolism [6,8,10,11]. Endocannabinoid concentrations, especially AEA and 2-
AG, are increased in obesity and are not only positively associated with anthropometric 
measures such as BMI and body fat percentage but also with decreased insulin 
sensitivity and triacylglycerol concentrations (2-AG) [6,9]. Studies with cannabinoid 
receptor 1 antagonists showed anorexigenic effects, increased glucose uptake by 
muscles, and inhibition of lipogenic enzymes suggesting that endocannabinoids are 
involved in pathways regulating energy intake and metabolism. However, knowledge 
about exact mechanisms is still largely missing and under further investigation [5,7,9,12].  
Type II diabetes mellitus 
Impaired glucose metabolism and insulin resistance at an early stage can be categorized 
as pre-diabetes, a reversible condition where patients are at high risk of developing 
T2DM [13]. Overweight and obesity have been estimated to be responsible for around 
90% of the T2DM cases. Excess weight causes increased circulating free fatty acids (FFA) 
concentrations via multiple routes (e.g., meal derived and enhanced lipolysis), which in 
turn stimulate insulin resistance [14]. Diets low in carbohydrates and, subsequently, 
often high in protein have beneficial effects on insulin sensitivity, especially when 
applied with energy restriction for weight loss or maintenance [4]. For diabetes pre-
vention, lifestyle interventions have been of great interest [15]. Diabetic patients have a 
two to fourfold increased risk to die from CVD [16], next to other co-morbidities. 
Diabetes is a risk factor for hypertension and hyperlipidemia [17] and may cause macro- 
and microvascular complications [18,19]. 
  




Cardiovascular disease (CVD) is the leading cause of death worldwide: with 
approximately 17.9 million deaths per year, CVD accounts for around 31% of all deaths 
worldwide [20]. CVD involves multiple disorders related to heart and blood vessel-
related issues, such as coronary heart disease (CHD), cerebrovascular disease, and peri-
pheral arterial disease [21]. As the leading underlying cause for CVD, atherosclerosis has 
been identified. Atherosclerosis is a chronic disease of the blood vessels causing plaque 
development in the arterial walls, called atherosclerotic lesions. Those lesions not only 
narrow the arteries, thus impairing the blood flow to vital organs, but plaques can also 
rupture and cause myocardial infarction or strokes. A precursor of atherosclerosis is 
endothelial dysfunction (discussed below), followed by lipid accumulation in the arterial 
vessel wall, inflammation, and finally, plaque formation [22].  
Important factors contributing to a high risk for severe CVD development are increasing 
age, an unhealthy lifestyle, overweight, diabetes, hyperlipidemia, and hypertension. Age 
is one of the main risk factors for many non-communicable diseases, such as CVD and 
T2DM [21,23], and therefore warrants appropriate health care [24]. According to the 
WHO, the proportion of older adults above the age of 60 is projected to double in 2050 
and health care costs are expected to increase accordingly [25]. Improving behavioral 
risk factors, such as an unhealthy diet, physical inactivity, and cigarette smoking may 
largely prevent CVD development [20]. Therefore, lifestyle-related treatments, for 
instance, nutritional interventions, are of great interest to lower CVD risk.  
Cardiometabolic risk factors 
Typical risk factors for the development of CVD are hypertension and hyperlipidemia. 
Hypertension, one of the strongest risk factors for developing CVD, has been defined as 
increased systolic and/or diastolic blood pressure (>140 mmHg, respectively >90 mmHg) 
[26]. Overall, approximately 30 - 45% of Europe’s population suffers from elevated blood 
pressure levels, with a higher prevalence with increasing age. Hypertension has been 
related to several CV diseases and events, such as peripheral arterial disease, stroke, and 
heart failure [27]. 
In hyperlipidemia, patients have abnormally high circulating blood lipid concentrations, 
such as LDL-cholesterol and triacylglycerol (TAG), which are carried through the 
bloodstream by lipoproteins [28]. Elevated blood lipid concentrations have been 
associated with increased CVD risk [29].  
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Vascular (dys)function 
Vascular function can be disrupted in multiple ways, such as stiffening of the arterial wall 
or dysfunction of the endothelial layer. The arterial wall consists of several layers, 
containing collagen fibers in the outer layer (adventitia), connective tissue and smooth 
muscle cells in the middle layer (media), and endothelial cells in the inner layer (intima) 
[30,31]. 
Endothelial function 
The endothelium is a monolayer of endothelial cells between the vascular lumen and 
the vascular wall, and can be found in all sizes of blood vessels. A healthy endothelium 
is not only a physical layer, it also acts as a functional layer and exerts several 
physiological functions in response to physical or chemical stimuli. It can affect cellular 
adhesion, blood coagulation, inflammation of the vessel wall, and vasomotion by 
releasing or reacting to vasoactive substances, leading to vasodilation or constriction. 
One of those vasoactive substances is nitric oxide (NO), which is produced by endothelial 
NO synthase (eNOS) from the precursor L-arginine upon shear stress due to increased 
blood pressure. NO leads to a relaxation of the arterial wall causing vasodilation, which 
then, in turn, reduces the primary stimuli shear stress [32,33].  
Bioavailability of NO can be reduced by chronic inflammation and increased levels of 
oxidative stress resulting in endothelial dysfunction. Besides, high levels of oxidative 
stress can induce a pro-thrombotic state by increasing the expression of cellular 
adhesion molecules and thereby initiating atherosclerotic plaque development by in-
creasing leucocyte affinity [34]. Endothelial dysfunction increases with age, elevated 
LDL-cholesterol concentrations, diabetes, hypertension, and obesity [35,36].  
Endothelial function can be assessed by the non-invasive, ‘gold-standard’ technique 
flow-mediated dilatation (FMD) of the brachial artery. This measurement uses an ultra-
sound technique to visualize the brachial artery. By analyzing the arterial diameter with 
and without a stressor, endothelial function can be assessed. For FMD, inflation of a 
blood pressure cuff on the forearm of the participant induces reactive hyperemia during 
the flow occlusion and shear stress after releasing the cuff. This shear stress causes nitric 
oxide (NO) release from the endothelium, which finally leads to a measurable dilation of 
the brachial artery. The percentage diameter increase during the reaction period is the 
final FMD value implicating that a lower FMD is related to stiffer arteries [32]. An FMD 
higher than 3% of the baseline diameter has been considered to be healthy [37] and 
each percentage point (pp) decrease in FMD has been related to an 8% increased risk 
on CVD [38]. 
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Another method of assessing endothelial function is the relatively new, carotid-artery 
reactivity (CAR) measurement. This method evaluates the effect of a cold pressor test 
(CPT) on the carotid artery diameter. For the CPT, the participants’ hand is placed in a 
bucket with ice-cold water (~4°C) to activate the sympathetic nervous system, which 
then affects the carotid artery diameter. CAR has also been suggested as a valuable 
measure for CV risk assessment [39,40]. 
Arterial stiffness 
In a healthy condition, arteries can flexibly adjust to blood pressure changes during the 
cardiac cycle by distension. Conditions like hypertension, atherosclerosis, hyper-
cholesteremia, diabetes, and increasing age lead to structural changes in the artery 
walls. Thickening or increased collagen production in the artery wall in the dispense of 
elastin fibers results in stiffening of the arteries [31,41]. Stiffening of the arteries is a 
predictor of CVD, such as stroke, heart failure, myocardial infarction, and dementia [31]. 
Arterial stiffness can be assessed by carotid-to-femoral pulse wave velocity (PWVc-f), a 
‘gold-standard’ measurement. PWVc-f measures the speed of the blood flow through the 
body by dividing the distance by the transit time between the two measurement points 
and is considered as a direct measure of arterial stiffness [42]. PWVc-f values largely 
depend on age, but a PWVc-f higher than 13 m/s has been associated with an increased 
risk for CV mortality [43]. A second option to assess arterial stiffness is the augmentation 
index (AIx). The AIx is considered as an indirect measure of arterial stiffness and provides 
additional information on pulse wave reflections in the arteries [42]. Both measures 
have been associated with a higher CV risk when increased [44].  
Structure of the microvasculature  
The retinal microvascular structure gives an indication for other microvascular systems 
in the human body and has been shown to correlate with age, blood pressure, and 
arterial stiffness [45-47]. It can be non-invasively assessed by retinal images where the 
arteriolar and venular diameters can be measured and a ratio of arteries and veins can 
be calculated. Beneficial effects on CVD outcomes have been related to increased 
arteriolar and decreased venular diameters in women [48].  
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Dietary intervention strategies 
Modifiable risk factors cause 70% of all CVD worldwide. Among those causes, diet plays 
a key role as it has been shown to be responsible for 45% of all premature CVD-related 
deaths worldwide. Diets low in fruits, vegetables, nuts, legumes, and fibers are in the 
top 10 of diet-related causes [49,50]. High intakes of saturated dietary fat have been 
shown to enhance serum lipoprotein concentrations and to impair vascular endothelial 
function [51,52]. Diet and exercise intervention strategies have been shown to 
beneficially affect CVD and T2DM incidence or mortality rates in several long-term 
studies [53-56]. Many of those lifestyle interventions aim to reduce body weight, 
thereby reducing the impact of weight as a critical risk factor for CVD and T2DM 
development. Dietary strategies such as high-protein diets or plant-based diets have 
been discussed to affect CVD and T2DM development beneficially. However, results are 
inconclusive [4]. 
The PREVIEW study - diabetes prevention 
The effects of a higher dietary protein intake on T2DM prevention have been assessed 
in a large international trial: the PREVIEW study (PREVention of diabetes through 
lifestyle Intervention and population studies in Europe and around the World) [57]. In 
this thesis, results from a substudy of the PREVIEW Maastricht cohort, which investi-
gated the effects of dietary protein on appetite, energy balance, and CVD risk are 
presented in chapters 2 to 4. The PREVIEW intervention started with an 8-week weight-
loss period, followed by a three-year lifestyle intervention. For the lifestyle intervention, 
participants either followed a moderate-protein, moderate-glycemic index (GI) diet or a 
high-protein, low-GI diet combined with either moderate or high-intensity exercise [55].  
Dietary protein  
Dietary protein accounts for around 15 energy % (EN%) of the macronutrients in the 
standard Western diet. When intakes are elevated (~20 to 30 EN% from dietary protein), 
dietary protein has been shown to effectively help with body weight management and 
body composition by affecting energy metabolism and promoting satiety via multiple 
pathways, such as secretion of anorexigenic hormones, circulating amino acids, and 
energy expenditure [4]. A higher protein content has been discussed to affect energy 
balance. Due to increased adenosine triphosphate (ATP) requirements for metaboli-
zation and oxidation of protein, the diet-induced thermogenesis (DIT) is elevated after 
consumption of high-protein diets.  Additionally, energy balance has been shown to be 
negative with a higher protein intake, even with isocaloric diets [58]. Stimulating protein 
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synthesis rate by increased protein intake might help to preserve fat-free mass (FFM) 
and thereby maintain energy expenditure in conditions of restricted energy intake, when 
energy expenditure typically decreases [4,58].  
A higher dietary protein content has not only been beneficial in energy-restricted diets 
but may also prevent overweight and obesity in energy-balanced conditions. Whether 
dietary protein exerts effects on CVD outcome parameters independent of weight loss 
remains inconclusive. In general, protein type, amino acid composition, and origin of the 
protein seem to largely influence specific markers [4], but the assessment of inde-
pendent effects of particular protein types and amino acids is challenging. However, 
especially plant-based diets containing high amounts of plant protein combined with 
some animal-protein sources such as lean meat and fish have been suggested to 
minimize CVD risk [59].  
Plant-based diets 
Plant-based diets have been associated with a reduced risk of developing CVD [60-62]. 
A meta-analysis of prospective cohort studies showed that a vegetarian dietary pattern 
was associated with a decreased risk of 28% for coronary heart disease [61]. Plant-based 
diets contain high amounts of plant protein, fiber, unsaturated fatty acids (UFAs), and 
phytochemicals. All these components have been associated with improvements in CVD 
risk [61,63]. They can improve LDL-cholesterol levels by their plant sterol content but 
also by replacing saturated fats with unsaturated fats, viscous fibers which can enhance 
short-chain fatty acid (SFAs) production, and proteins, providing amino acids involved in, 
e.g., cholesterol metabolism and NO production or serving as vehicles for the plant 
sterols and fibers [61]. 
Plant-based diets are mainly or entirely based on plant-derived products. Typical 
examples of plant-based diets are the Mediterranean diet, the Nordic diet, the DASH 
diet (Dietary Approaches to Stop Hypertension), and vegetarian and vegan diets. The 
first three diets focus on high amounts of fruits and vegetables, legumes, whole grains, 
unsaturated fats, (fatty) fish, and low intake of red and processed meat. In contrast, the 
vegetarian diet allows egg and dairy products but renounce meat products entirely, and 
the vegan diet even abandons any sort of animal-derived product, including dairy 
products [61].  
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Soy products 
The soybean (Glycine Max) forms an essential component of the traditional Asian diet 
and of vegetarian diets in the Western world. Soybeans are particularly rich in plant 
proteins, accounting for approximately 36 to 46% of the total energy (En%). Soy protein 
contains all essential amino acids and has been classified as high-quality protein. The 
protein quality can be specified by the digestible indispensable amino acid score (DIAAS) 
[9], which indicates that soy can be classified as a high-quality protein source [11,12]. 
Additionally, soybeans contain low amounts of carbohydrates and high amounts of 
polyunsaturated fatty acids (PUFAs), accounting for 62% of the total fat content 
(approximately 11.3 g per 100 g soybeans). Additional compounds are high doses of 
phytoestrogens, also called isoflavones [64,65], mainly daidzein (50%) and genistein 
(40%) [65]. Daidzein can be taken up in its natural form or can be metabolized to equol 
in the human intestine by around 50 - 55% of the Asian and 20 – 35 % of the Western 
population. Effects of equol are less understood yet, but it has been suggested to have 
even stronger health effects than the other isoflavones [66,67]. Another component of 
soy is the polyamine spermidine, a natural autophagy inducer which has been inversely 
associated with CVD in epidemiological studies [68]. 
Soybeans can be consumed in a large variety of products such as beans, soy milk, protein 
powder, or fermented soy products. This dissertation examines the effects of soy nuts 
on cardiometabolic and vascular health (Chapter 5). The soy nuts were roasted, unsalted 
whole soybeans including the peal, to enable a combined effect of a high plant-protein 
and phytoestrogen content with fibers, minerals, and unsaturated fats. Unlike other soy 
products, soy nuts have relatively high isoflavones concentrations [69-71].  
Outline of the thesis  
The aim of this thesis was to investigate the effects of dietary interventions with a mixed 
high-protein content or soy nuts on several metabolic health and vascular function 
markers in adults (see Figure 1.1). This thesis presents the results of two human 
intervention trials, a substudy of the PREVIEW-cohort [57] performed in Maastricht and 
an intervention study with soy nuts. In chapters 2 to 4, results of the PREVIEW substudy 
are presented. In the PREVIEW substudy, post-obese, pre-diabetic participants stayed 
for two days in a metabolic chamber at the university after almost three years of lifestyle 
intervention of the original study, where participants received either a high-protein or 
moderate-protein diet. We have examined the effects of a higher dietary protein and 
soy nut intake on several measures of cardiovascular and metabolic health during these 
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two days. Effects on markers of appetite and gut peptides (Chapter 2), the role of 
endocannabinoids in energy balance (Chapter 3), and cardiometabolic health and 
vascular function (Chapter 4) during a high-protein diet are presented. Chapter 5 
describes the results of a longer-term human intervention trial, where the effects of soy 
nut consumption on cardiometabolic health and vascular function were studied in older 
adults. This study used multiple measures for cardiovascular health. In the last chapter     
(Chapter 6), main findings of these studies are summarized, combined in a general 
discussion, and placed into a broader perspective. 
 
 Figure 1.1: Proposed health effects of dietary protein investigated in this thesis. ↑ = increase;                    
↓= decrease; ? = unclear effects. Created with BioRender.com. 
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Background: Favorable effects of a high-protein/moderate-carbohydrate (HP/MCHO) 
diet after weight loss on body weight management have been shown. To extend these 
findings, associations between perception of hunger and satiety with endocannabinoids, 
and with glucagon-like peptide-1 (GLP-1) and polypeptide YY (PYY) were assessed.  
Design: At approximately 34 months after weight loss, 22 female and 16 male 
participants (mean age 64.5 ± 5.9 years; body mass index (BMI) 28.9 ± 3.9 kg/m²) 
completed a 48 h respiration chamber study. Participants were fed in energy balance 
with a HP/MCHO diet with 25%:45%:30% or a moderate-protein/high-carbohydrate 
(MP/HCHO) diet with 15%:55%:30% of energy from protein:carbohydrate:fat. Endo-
cannabinoids and related compounds, relevant postprandial hormones (GLP-1, PYY), 
hunger, satiety, and ad libitum food intake were assessed.  
Results: HP/MCHO versus MP/HCHO reduced hunger perception. The lower 
decremental area under the curve (dAUC) for hunger in the HP/MCHO diet (–56.6% 
compared to MP, p < 0.05) was associated with the higher AUC for 2-arachidonoyl-
glycerol (2-AG) concentrations (p < 0.05). Hunger was inversely associated with PYY in 
the HP/MCHO group (r = −0.7, p < 0.01). Ad libitum food intake, homeostatic model 
assessment for insulin resistance (HOMA-IR) and incremental AUCs for gut peptides 
were not different between conditions.  
Conclusion: HP/MCHO versus MP/HCHO diet-induced reduction in hunger was present 
after 34 months weight maintenance in the post-obese state. HP/MCHO diet-induced 
decrease of hunger is suggested to interact with increased 2-AG and PYY concentrations. 
  
High-protein diet, appetite, gut peptides, and endocannabinoids | CHAPTER 2 
 25 
INTRODUCTION 
In 2016, 39% of the adult population worldwide was considered overweight and 13% 
obese [1]. A positive energy balance is one of the most critical underpinnings for this 
development, posing a major risk for the development of chronic diseases including 
type-II diabetes (T2D) and cardiovascular disease [2]. 
While successful dieting and weight maintenance are essential to long-term improve-
ments of metabolic disease, weight maintenance remains especially challenging. For 
weight reduction as well as long-term weight maintenance, dietary protein was 
suggested as being potentially helpful due to the notion that it appears to be more 
satiating than carbohydrates or fat in an acute setting [3–7], and therefore may support 
the reduction of food intake [8]. Additionally, a ketogenic state, induced by a short- or 
medium-term high-protein, low-carbohydrate condition [9,10], has been suggested as a 
contributor to protein-related appetite regulation. In addition to increased satiety, 
protein was shown to have sparing effects on fat-free mass (FFM) during weight 
reduction and weight maintenance [11,12], while energy expenditure increased 
[5,11,13,14].  
The endocannabinoid system is critically involved in the regulation of energy balance 
and in the pathophysiology of metabolic disorders [15–17]. The system comprises 
endogenous lipids, the cannabinoid receptor 1 and 2 (CB1 and CB2) and the enzymatic 
machinery involved in the synthesis and degradation of endocannabinoids [15]. The best 
characterized endocannabinoids are the N-ethanolamide of arachidonic acids, known as 
anandamide (AEA) and the glycerol ester of arachidonic acid or 2-AG. The lipid 
derivatives and endocannabinoid-related compounds oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA) are synthetized together with AEA and share structural 
similarities, but do not bind to cannabinoid receptors. AEA and 2-AG both correlate 
positively with markers of obesity and metabolic disorders in humans [18–20]. OEA 
decreases appetite and favors weight loss and lipolysis by acting through peroxisome 
proliferator-activated receptor-α (PPAR-α), contrasting the metabolic effects of the 
endocannabinoid-dependent CB1 receptor activation [21], which has been linked to 
obesity promotion [17]. Pregnenolone (PREG), a neurosteroid precursor, has been 
suggested to be a negative regulator of endocannabinoids by experimental data [22] and 
thereby prevents overstimulation of the cannabinoid receptor [22]. While endo-
cannabinoids have been assessed with regard to energy balance [17,23] and fat intake 
[20], the role of dietary protein in endocannabinoid signaling remains unknown.  
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In addition, satiety-related gut peptides such as GLP-1 and PYY, have been reported to 
be increased [24,25] in response to high-protein intake compared to high-carbohydrate 
or high-fat intake. Both GLP-1 and PYY have incidentally been linked to increased satiety 
and reduced food intake [26]. However, based on the literature, individual perception 
of appetite and appetite-related gut peptides was not consistently associated [27]. 
Therefore, the use of gut peptides as a direct biomarker for perceived appetite alone 
appears insufficient [28]. 
The present study aimed to assess the effects of a high-protein/moderate-carbohydrate 
(HP/MCHO) versus moderate-protein/high-carbohydrate (MP/HCHO) diet in the post-
obese state after weight loss, on the association between perception and physiology of 
hunger and satiety in energy balance, in a controlled respiration chamber setting. 
Especially, the protein-content-related differences in concentrations of endocanna-
binoids and related compounds as well as their potential association with hunger and 
satiety perception were assessed. We hypothesized that also in the post-obese phase, a 
high-protein/moderate-carbohydrate diet would be more satiating compared to a 
moderate-protein/high-carbohydrate diet, evidenced by higher satiety ratings and lower 
hunger ratings, possibly associated with changes in concentrations of endocanna-
binoids and related compounds, and with increased satiety hormone concentrations. 
 
MATERIALS AND METHODS 
The study was registered at ClinicalTrials.gov (NCT01777893), was performed in line with 
the Declaration of Helsinki, and was approved by the Medical Research Ethics 
Committee of Maastricht University Medical Centre (METC). All participants provided 
written informed consent for participation. The study was performed at Maastricht 
University from February 2017 until February 2018.  
Participants 
A subgroup of 40 participants was recruited from the PREVention of diabetes through 
lifestyle intervention and population studies in Europe and around the World (PREVIEW) 
cohort [29] at Maastricht University in the Netherlands, of which 2 dropped out due to 
a lack of time (Supplementary Figure S2.1). Sample size calculation was based on energy 
expenditure [30]. The PREVIEW intervention study (Prevention of Diabetes through 
lifestyle intervention and population studies in Europe and around the World, EU 
seventh Framework Program, grant agreement no. 31205) is a multinational, multi-
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center, 2 x 2 factorial, randomized controlled trial aimed at finding the most effective 
lifestyle intervention to prevent the development of T2D in predisposed individuals. 
Individuals were between 25 and 70 years of age and had a Body Mass Index (BMI) above 
25 kg/m2. Pre-diabetes, which was defined by a fasting plasma glucose concentration 
between 5.6 and 6.9 mmol/L and/or a 2 h plasma glucose between 7.8 and 11.0 mmol/L 
following an oral glucose tolerance test (OGTT) [29], was an inclusion criterion for 
participation. Exclusion criteria for this respiration chamber sub-study were claustro-
phobia, smoking, and previous cardiovascular events, next to the exclusion criteria for 
the PREVIEW study [29]. Written informed consent was obtained from all participants 
before starting the experiment.  
Experimental design 
Detailed information on the PREVIEW intervention study design, interventions, subject 
recruitment, primary and secondary endpoints, and baseline characteristics have been 
published before [29]. In short, an 8 week weight-reduction period by means of a low-
energy diet was followed by 34 months of a randomized intervention comprising four 
treatment groups: MP/HCHO with moderate-glycemic index (GI), or a HP/MCHO diet 
with low-GI, combined with either moderate- or high-intensity physical activity in a 
parallel design. In close proximity to the last clinical investigation day (after 34 months) 
of the PREVIEW intervention, a subgroup of participants underwent a 48 h experiment 
in the respiration chamber to assess specific HP/MCHO intake-related aspects of hunger 
and satiety regulation. Participants arrived at the Metabolic Research Unit Maastricht 
(MRUM) research facilities in the morning after an overnight fast from 22:00 h the night 
before. The respiration chamber experiment started at 9:30 h. Participants had fixed 
bedtimes in the respiration chambers from 11:30 h until 7:30 h and were not allowed to 
sleep during the daytime or to exercise. 
Anthropometric measurements 
Body weight and body composition (BOD POD®, Life Measurement Inc., Concord, CA, 
USA) were measured before the respiration chamber experiment was started. Height 
was measured using a wall-mounted stadiometer during screening. 
Respiration chamber 
The respiration chambers are 14 m3 airtight rooms with a controlled climate and 
furnished with a bed, chair, table, intercom, TV, computer, sink, and toilet. Continuous 
fresh air ventilation at a rate of 70 – 80 l/min was used and measured with a dry gas 
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meter (G6, gasmeterfabriek Schlumberger, Dordrecht, the Netherlands). O2 and CO2 
concentrations were continuously measured by open-circuit ventilated indirect 
calorimetry, using dual pairs of infrared CO2 analyzer (ABB/Hartman and Braun Uras, 
Frankfurt a.M., Germany) and paramagnetic O2 analyzers (Servomex 4100, 
Crowborough, England and ABB/Hartman and Braun Magnos, Frankfurt a.M., Germany) 
[31]. Total energy expenditure (EE) was calculated according to the formula of Weir [32].  
Diets and energy intake 
Participants received either a MP/HCHO (15%:55%:30% of energy from protein: 
carbohydrate:fat) or a HP/MCHO (25%:45%:30% of energy from protein:carbohydrate: 
fat) diet, according to their previous intervention group during the PREVIEW study. To 
keep menus as comparable as possible, the basis of all meals was the same between 
groups, combined with either carbohydrate- or protein-rich food items. Participants 
were asked to pay special attention to their prescribed study diet during the week before 
the experiment. All meals were provided in energy balance according to individual 
energy requirements during the respiration chamber session. The daily energy require-
ment was estimated by calculating the basal metabolic rate (BMR) with the use of fat 
mass (FM) and fat-free mass (FFM), which was then multiplied by a physical activity index 
of 1.35, based on previous respiration chamber experiments [33]. Dietary intake was 
divided over three meals with 20% of the daily energy requirement for breakfast (at 9:15 
h) and 40% for both lunch (at 13:00 h) and dinner (at 17:45 h). No other food products 
were allowed for consumption. Water consumption was allowed throughout the study 
at the participants’ convenience and unsweetened coffee or tea were served at several 
time points. For the ad libitum brunch after the 48 h in the respiration chamber, 
participants received a buffet style meal. This meal was the same for the two 
intervention groups and comparable to the chamber breakfast from the days before, 
but not diet-specific and including choices of carbohydrate- or protein-rich options. Total 
energy and macronutrient intake were evaluated afterwards. 
Appetite profile 
Subjective perception of appetite comprising hunger, fullness, and satiety was measured 
by 100 mm anchored visual analogue scales (VAS) from “not at all” to “very” during day 
2 in the respiration chamber [34]. Questionnaires were scored before and 30 minutes 
after each meal, as well as once in between the meals. In the case of a simultaneous 
blood draw, questionnaires were done before the blood draw. The incremental area 
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under the curve (iAUC) was calculated for satiety and fullness perception, and the dAUC 
was calculated for hunger perception using the trapezoidal rule [35].  
Metabolic parameters 
Fasting blood samples were taken from an antecubital vein by venipuncture on the first 
and last day of the respiration chamber study for the analysis of fasting glucose, insulin, 
β-hydroxybutyrate, and triacylglycerol. On the second day, a venflon catheter (Becton, 
Dickinson and Company, Franklin Lanes, NY, USA) was placed in the antecubital vein for 
fasted and postprandial blood collections throughout the day for collection of 
endocannabinoids and related compounds, glucose, insulin, GLP-1, and PYY. Blood 
samples were drawn directly before and 30, 60, 90, and 120 minutes after all three 
meals. Except for serum samples, all samples were immediately stored on ice, 
centrifuged for 10 minutes at 1500 g at 4 °C, immediately distributed in aliquots, and 
stored at −80 °C until analysis at the end of the study, enabling all samples from one 
participant to be analyzed in the same run. Serum samples were kept at room 
temperature for 30 minutes to allow clotting before centrifugation (10 minutes at 1500 
g at 4 °C). For endocannabinoid and related compounds measurements, samples were 
collected immediately before, 60 minutes after meals, and 120 minutes after dinner. 
The AUC was calculated for the endocannabinoids and related substances. The iAUC was 
calculated for GLP-1, PYY, glucose, and insulin using the trapezoidal rule [35]. 
Endocannabinoids and endocannabinoid-related compounds 
For endocannabinoid and endocannabinoid-related compound analysis, ethylene-
diaminetetraacetic acid (EDTA) tubes (Becton, Dickinson and Company, Franklin Lakes, 
NY, USA) were used. Syringes and EDTA tubes were ice-chilled before blood collection 
and storage cups were prepared with 1% phenylmethylsulfonyl fluoride (PMSF) solution 
(10 mg PMSF in 1 ml methanol) and 5% 1N hydrochloric acid at final concentration. 
Samples were snap frozen in liquid nitrogen immediately.  
The extraction, purification, and quantification of AEA, PEA, OEA, and 2-AG from blood 
require a set of different biochemical steps as described previously [19,36]. Samples 
were then subjected to isotope-dilution liquid chromatography-chemical ionization-
tandem mass spectrometric analysis. Mass spectral analyses were performed on a TSQ 
Quantum Access triple quadrupole instrument (Thermo-Finnigan, San Jose, CA, USA) 
equipped with an APCI source (atmospheric pressure chemical ionization) and operating 
in positive ion mode [37]. Pregnenolone was extracted from plasma by a simple solid-
phase extraction method using reverse-phase C18 columns according to the method 
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described in Vallée et al. [22] and analyzed with a GC-MS/MS (gas chromatography-
tandem mass spectrometer) XLS Ultra Thermo mass spectrometer (Thermo-Finnigan, 
San Jose, CA, USA) via an AS3000 II autosampler. 
GLP-1 and PYY 
For analyses of GLP-1 and PYY concentrations, EDTA-aprotinin tubes (Becton, Dickinson 
and Company, Franklin Lakes, NY, USA) with added dipeptidyl peptidase IV inhibitor (10 
ml/L blood) were used. Syringes and EDTA-aprotinin tubes were ice-chilled before blood 
collection and samples were snap frozen in liquid nitrogen immediately. Total GLP-1 [38] 
and PYY3-36 concentrations were both determined using a radioimmunoassay method. 
For the PYY assay, a 125-Iodine label was used and data were analyzed with RIACALC 
(Pharmacia, Freiburg, Germany).  
Glucose and insulin 
Plasma for colorimetric glucose analysis (Roche Diagnostic Systems, Woerden, the 
Netherlands) was collected in sodium fluoride tubes (Becton, Dickinson and Company, 
Franklin Lakes, NY, USA). Serum for insulin analysis was collected in serum separator 
tubes (Becton, Dickinson and Company, Franklin Lakes, NY, USA). Samples were used to 
analyze fasting and postprandial insulin concentrations with a human insulin-specific 
radioimmunoassay (Linco Research, St Charles, MO, USA). Insulin sensitivity was 
estimated by calculating the HOMA-IR [39]. 
β -Hydroxybutyrate  
EDTA vacutainer tubes (Becton, Dickinson and Company, Franklin Lakes, NY, USA) were 
used to collect plasma samples for β-hydroxybutyrate concentrations analysis with gas 
chromatography-mass spectrometry (GC-MS) quantification (Varian factor four VF-5 ms, 
15 mx 0.25 mm * 0.1 µM with GCMS ms 7890A-7000c, Agilent, Santa Clara, CA, USA). 
Triacylglycerol 
Serum samples (Becton, Dickinson and Company, Franklin Lakes, NY, USA) were used to 
analyze fasting triacylglycerol (GPO Trinder; Sigma-Aldrich Corp., St. Louis, MO, USA). 
Statistical analysis 
All statistical tests were performed using SPSS for Macintosh (Version 25; SPSS Inc., 
Chicago, IL, USA). Data are presented as means ± standard deviations (SDs), unless 
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otherwise indicated. Significance was defined as p < 0.05. Differences between both 
groups before and during their respiration chamber stay were calculated using ANOVA, 
and repeated measures ANOVA with BMI or body-fat percentage as a covariate, if 
appropriate. Not normally distributed data, as determined with the Shapiro–Wilk test, 
were log-transformed and tested on normality again. Partial correlation coefficients 
were calculated to assess associations between protein intake, appetite, gut peptides, 
and endocannabinoids, adjusted for BMI and fat percentage, if appropriate. 
 
RESULTS 
Study participants  
The subject characteristics for the MP/HCHO and HP/MCHO group at baseline of the 
respiration chamber experiment are summarized in Table 2.1. Twenty participants 
started the respiration chamber experiment in the HP/MCHO condition and 18 
participants in the MP/HCHO condition. The two groups were not different with regard 
to age, anthropometric variables, and fasting glucose and insulin concentrations prior to 
the respiration chamber experiment. Only triacylglycerol (TAG) was higher in the 
MP/HCHO group at baseline. 
 
Table 2.1: Subject characteristics of the moderate/high carbohydrate (MP/HCHO), and high-
protein/moderate-carbohydrate (HP/MCHO) group at baseline of the respiration chamber experiment. 
 
MP/ HCHO  
(n = 18) 
HP/ MCHO  
(n = 20)  
N (f/m)  18 (9/9) 20 (13/7) 
Age (year) 65.1 ± 5.8 64.0 ± 6.2 
BMI (kg/m2) 29.0 ± 3.8 28.9 ± 4.0 
Body-fat (%) 39.5 ± 8.1 40.7 ± 7.7 
Fat mass (kg) 33.9 ± 7.1 34.8 ± 8.8 
Fat-free mass (kg) 52.5 ± 10.9 50.8 ± 11.3 
Glucose (mmol/L) 5.8 ± 0.4 5.7 ± 0.5 
Insulin (μU/ml) 14.8 ± 7.6 14.4 ± 4.9 
HOMA-IR 3.8 ± 1.8 3.6 ± 1.3 
TAG (mmol/L) 1.5 ± 0.7 1.2 ± 0.6* 
Values are means ± standard deviation (SD). BMI: Body Mass Index; HOMA-IR: Homeostatic Model 
Assessment of Insulin Resistance; TAG: triacylglycerol. *p < 0.05. 
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24-hour hunger and satiety perception  
Baseline appetite profile was not different between conditions. Hunger perception (VAS) 
based on the decremental area under the curve during the whole day was significantly 
lower in the HP/MCHO diet compared to the MP/HCHO diet (−56.6%, F = 5.89, p < 0.05, 
Figure 2.1). Looking at the individual meals, specifically breakfast (−83%; F = 10.30, p < 
0.01) seemed to have contributed to the overall difference between the intervention 
groups. The differences in hunger ratings could not be explained by differences in energy 
balance (MP/HCHO: 0.2 ± 0.9 megajoule (MJ), HP/MCHO: −0.5 ± 0.9 MJ; F = 6.03, p < 
0.05) [30] between the two intervention groups. There were no differences in satiety or 
fullness ratings between the two groups (Figure 2.1).  
 
Figure 2.1: Visual analogue scales for appetite for MP/HCHO (black) and HP/MCHO (grey) groups. 
Hunger is presented as dAUC, fullness and satiety as iAUC. *P < 0.05. Values are means ± SD. Differences 
between groups were calculated with a One-Way ANOVA. MP/HCHO = moderate protein/ high 
carbohydrate; HP/MCHO = high protein/moderate carbohydrate; iAUC = incremental area under the 
curve; dAUC = decremental area under the curve; mmVAS = millimeter visual analogue scale.  
 
Metabolic parameters 
Endocannabinoids and related compounds concentrations throughout the day 
2-AG showed increased concentrations 60 minutes after each meal, then decreasing 
back to baseline concentrations before the next meal (Figure 2.2). Around lunch, there 
was a significant time-by-treatment interaction for 2-AG (F = 6.61, p < 0.05). In addition, 
High-protein diet, appetite, gut peptides, and endocannabinoids | CHAPTER 2 
 33 
the AUC of 2-AG was significantly higher in HP/MCHO compared to MP/HCHO (4351 ± 
1616 pmol/L versus 3368 ± 1552 pmol/L, F = 4.67, p < 0.05) and the post-meal change 
in 2-AG during dinner was positively related to the change in hunger (r = 0.37, p < 0.05). 
Post-meal changes of 2-AG were not related to changes in glucose, insulin, GLP-1, or PYY 
during any of the meals or to body weight or body composition. The postprandial change 
in 2-AG after dinner was positively associated with the change in pleasantness ratings (r 
= 0.425, p < 0.05). There was no clear meal associated pattern or higher protein/ 
moderate carbohydrate intervention related effect in other endocannabinoids and 
related compounds. However, we observed that OEA concentrations (AUC) were 
inversely associated with the change in TAG (Figure 2.3) throughout the 48 h of the 
experiment (r = −0.40, p < 0.05).  
 
Figure 2.2: (A) Postprandial responses and (B) area under the curve (AUC) of 2-AG in the MP/HCHO 
(black) and HP/MCHO (grey) group. Arrows indicating timepoint of meals. Values are means ± SD. 
MP/HCHO = moderate protein/high carbohydrate; HP/MCHO = high protein/moderate carbohydrate; 
2-AG: 2-arachidonoylglycerol. *P < 0.05. 
  




Figure 2.3: (A) AUC of change in TAG over 48 h in the MP/HCHO (black) and HP/MCHO (grey) group and 
(B) inverse association of OEA concentrations throughout the day and the change in TAG over 48h. 
Values are means ± SD. MP/HCHO = moderate protein/high carbohydrate; HP/MCHO = high protein/ 
moderate carbohydrate; TAG: triacylglycerol; OEA: oleoylethanolamide. *P < 0.05. 
 
Gut peptides, glucose, and insulin concentrations throughout the day 
Postprandial plasma GLP-1 and PYY concentrations are shown in Figure 2.4. No 
significant differences in GLP-1 and PYY response, expressed as iAUC, were found 
between the HP/MCHO and the MP/HCHO group (Figure 2.4). In the complete group, 
the dAUC of hunger was inversely associated with the PYY iAUC (r = 0.40, p < 0.05) 
however this was especially the case in the HP/MCHO group. We found a significant 
interaction between group and PYY iAUC with regard to hunger ratings (F = 7.47,                  
p < 0.05). In the HP/MCHO group, hunger (dAUC) was inversely associated with PYY 
(iAUC) concentrations (r = 0.71, p < 0.01; Figure 2.5), but not in the MP/HCHO group. 
GLP-1 was not associated with any of the subjective appetite assessments (hunger, 
fullness, and satiety). Neither PYY nor GLP-1 concentrations were associated with energy 
balance in any of the two intervention groups or with parameters related to glucose 
metabolism. Postprandial glucose concentrations were incidentally higher in the 
MP/HCHO group but both, glucose and insulin concentrations throughout the day 
(Figure 2.4) did not differ between the two intervention groups.  
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Figure 2.4: (A) Postprandial responses over time and (B) incremental area under the curves of GLP-1, 
PYY, glucose, and insulin in the MP/HCHO (black) and HP/MCHO (grey) group. Arrows indicating time-
point of meals. *P < 0.05. Values are means ± SD. Differences between groups were calculated with a 
One-Way ANOVA. MP/HCHO = moderate protein/high carbohydrate; HP/MCHO = high protein/ 
moderate carbohydrate; GLP-1 = glucagon-like peptide 1; PYY = peptide YY; iAUC = incremental area 
under the curve. 




Figure 2.5: Inverse association of hunger and PYY concentrations throughout the day in the MP/HCHO 
( ) and HP/MCHO ( ) group. Regression lines are shown in black (MP/HCHO) and grey (HP/MCHO,     r 
= 0.710, p = 0.001). MP/HCHO = moderate protein/high carbohydrate; HP/MCHO = high protein/ 
moderate carbohydrate; iAUC = incremental area under the curve; dAUC = decremental area under 
the curve; PYY = peptide YY. 
Fasted β-hydroxybutyrate and triacylglycerol concentrations 
Plasma β-hydroxybutyrate concentrations, a marker for fat oxidation, were not different 
between dietary conditions (MP/HCHO: 90.05 ± 87.61 μg/ml and HP/MCHO: 117.57 ± 
93.35 μg/ml). Baseline β-hydroxybutyrate was negatively associated with BMI (r = −0.35, 
p < 0.05) but was not associated with appetite perception or gut peptides. TAG 
concentrations increased in both intervention groups from pre- to post-respirations 
chamber measurement, but the increase was less pronounced (p < 0.05; Figure 2.3) in 
the HP/MCHO group compared to the MP/ HCHO group (0.23 ± 0.22 mmol/L versus 0.47 
± 0.35 mmol/L, respectively). 
Ad libitum energy intake after leaving the chamber 
Ad libitum energy intake (EI) (EI; MP/HCHO: 30.6% ± 10.4% energy requirement, 
HP/MCHO: 33.5% ± 12.4% energy requirement) as well as macronutrient content of 
meal choice (protein intake MP/HCHO: 18.5% ± 4.8% energy intake (%EI), HP/ MCHO: 
17.9% ± 4.0% EI; carbohydrate intake MP/HCHO: 50.2% ± 8.1% EI, HP/ MCHO: 46.9% ± 
7.5% EI; fat intake MP/HCHO: 30.3% ± 7.4% EI, HP/MCHO: 32.7% ± 6.0% EI) assessed 
during ad libitum brunch were not different between intervention groups. Ad libitum 
energy intake was not associated with excursions of gut peptides the day before or by 
insulin resistance, but it was negatively associated with total glucose concentrations 
(iAUC) of the previous day (r = −0.40, p < 0.05).  
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DISCUSSION 
This study demonstrates that a 48 hour high-protein/moderate-carbohydrate diet fed in 
energy balance under controlled conditions, reduced the perception of hunger and 
increased 2-AG concentrations after 34 months in a post-obese condition, compared to 
a moderate-protein, higher- carbohydrate diet. Hunger was inversely associated with 
PYY concentrations in the HP/MCHO group but not in the MP/HCHO group. High-
protein/moderate-carbohydrate intake led to a blunted increase in TAG compared to 
moderate-protein/high-carbohydrate intake, while changes in TAG were inversely 
associated with OAE. 
Reduced hunger and increased satiety or fullness have been previously found in studies 
applying acute high-protein diets, even in negative energy balance [13,14,25]. The 
decrease in hunger in the HP/MCHO versus the MP/HCHO group in the current study, 
however, did not translate into a decreased energy intake in the ad libitum brunch. 
Rather large differences in appetite ratings (e.g., ~40%) were necessary to actually result 
in differences in energy intake of e.g., ~20% in other studies, which applied a within 
subject design [8].  
Among the endocannabinoids and related compounds studied, 2-AG showed a 
consistent meal-related pattern with highest concentrations one hour post-prandially 
and lowest concentrations before the three meals. Interestingly, around all meals, the 
pattern of 2-AG concentrations was similar to that of concentrations in glucose, insulin, 
GLP-1, and PYY concentrations. However, in contrast to these parameters, 2-AG was the 
only one to be specifically affected by the higher-protein/moderate-carbohydrate 
content. Previous observations of plasma 2-AG dynamics around meals have been 
conflicting, from no meal-effect [36,40] to increased concentrations only after a hedonic 
meal, in both normal weight individuals [41] and in obese [42]. These data suggest that 
if food intake is driven by palatability of the food presented, rather than hunger, an 
increase in circulating 2-AG concentrations is observed, independent of the individuals’ 
BMI [41,42]. As higher 2-AG concentrations have been observed even before the actual 
consumption of palatable food, the authors have proposed an anticipatory role for this 
endocannabinoid in signaling the pleasure of the palatable food that is going to be eaten 
[41]. Regarding the possible hedonic component in endocannabinoid dynamics, desire 
to eat was not different between the intervention groups, and meals were described as 
equally pleasant in our study. However, postprandial changes in 2-AG were positively 
related to changes in pleasantness after dinner, therefore a hedonic effect cannot be 
excluded. No evidence can be found for a direct postprandial association of 2-AG with 
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excursions of PYY and GLP-1 on an individual meal basis, suggesting a gut peptide-
independent pathway of 2-AG in the current study. In contrast, 2-AG has been shown to 
be associated with GLP-1 [43] but not with appetite perception [41,43] previously. In the 
current study, however, postprandial changes of 2-AG were associated with changes in 
hunger after dinner. In our study, we characterized responses in participants who were 
still overweight, who had undergone a weight loss period for eight weeks followed by a 
34 month period of weight maintenance before the current experiment was started. It 
is possible that the participants studied have a hedonic response different from lean, 
healthy-weight individuals, which in part may explain the postprandial increase in   2-AG 
concentrations observed in both intervention groups as 2-AG concentrations has been 
shown to be associated with BMI [18,19]. Finally, a likely origin of the changes in 
circulating 2-AG concentrations may be the intestine. Indeed, studies in rats have shown 
that gustatory stimulation with fat, without actual food intake, leads to an increase in 
both 2-AG and AEA content in the small intestine, which then further favor fat con-
sumption through a positive feedback loop involving vagal afferents and the brainstem 
[44]. Accordingly, it has been shown that cheese with a specific fatty acid profile could 
influence plasma endocannabinoids in humans [45]. However, the role of other 
nutrients, especially protein on endocannabinoid concentrations, has never been 
studied before. To our knowledge, the current data are therefore the first evidence of a 
link between an increased protein/carbohydrate ratio and circulating 2-AG concentra-
tions. Further research is needed to investigate the potential impact on weight loss and 
weight maintenance of this observation.  
While AEA has been described as an orexigenic compound in the literature [20,36], PEA, 
OEA, and PREG were associated with anorexigenic effects [22,46–49]. OEA has been 
suggested to influence fat catabolism [50] and stimulate lipolysis [51]. While OEA was 
not associated with fat oxidation in the current study, the inverse relationship found 
between OEA and blunted TAG concentrations may be due to an increase in lipolysis. 
In addition, in the present study, research participants were assessed in a controlled 
respiration chamber setting, and were fed in energy balance, which could over-shadow 
the perception of hunger and satiety that people experience in a real-life situation. 
Finally, the fact that 2-AG and AEA behave differently should not be surprising, as they 
are synthetized through different pathways, which may further support a different role 
for the compounds in food intake regulation [52]. As for the origin of endocannabinoids 
and their related compounds, we and others have proposed that prandial-related 
changes in plasma AEA, 2-AG, OEA and PEA may primarily reflect changes in synthesis 
from the gastrointestinal tract [36].  
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Regarding the gut peptides, we found an inverse association between hunger and PYY 
concentrations in the HP/MCHO group only. PYY has previously been shown to be 
increased in response to a HP diet and was suggested to mediate the satiating effects of 
dietary protein [24]. Our data supports other literature proposing a ‘threshold’ level of 
protein to be necessary to exert effects on PYY-mediated impact on hunger [53,54]. PYY 
and GLP-1 concentrations have been linked to satiety and food intake [26], with rather 
weak associations [13]. GLP-1 release on the other hand has been primarily associated 
with dietary carbohydrates and fat and has been shown to be lower by high protein 
whilst satiety was increased compared to high carbohydrate [55]. Some evidence points 
to a stimulation of GLP-1 by a HP condition [56,57]. In comparison, PYY appeared to be 
stimulated by dietary protein content to a larger extent than GLP-1 [27,57]. However, 
changes in gut peptides by dietary protein content in the present study did not translate 
into changes in appetite perception. Relations between endogenous gut peptides and 
appetite ratings have shown hardly any, or conflicting results in the past [27], and have 
often been either absent [11], or weak [13]. Despite these discrepancies in subjective 
and objective appetite measures, appetite ratings by visual analogue scales have been 
shown to be highly reproducible [34] and may therefore still be important in assessing 
appetite next to physiologic measures. Taken together, the current study suggests that 
observed effects on 2-AG, hunger, and the association of PYY and hunger are nutrient-
related, since they are especially shown in the HP/MCHO group.  
While changes in TAG concentrations were blunted in the high-protein/moderate-
carbohydrate group, both intervention groups increased their TAG concentrations when 
comparing pre- and post-respiration chamber measurements. The general increase in 
TAG may be related to the sedentary circumstances the participants experienced 
throughout their 48 h stay [58,59]. High protein intake has previously been suggested to 
increase lipolysis [60] and inhibit lipogenesis [61], which may explain the blunted 
increase in TAG in the HP/MCHO condition compared to the MP/HCHO condition in the 
current study.  
The current study investigates the effects of a diet with higher protein and lower 
carbohydrate content compared to a diet with lower protein and higher carbohydrate 
content. Although there is some evidence describing the role of protein over 
carbohydrate on hunger perception [11], the current study design is not sufficient to 
clearly allocate the effect to one of the two macronutrients. To assign the described 
effects on 2-AG, hunger and PYY, and TAG, conclusively to a high protein or moderate 
carbohydrate level, or to a combination of both, longer follow-up studies are needed. 
  




In conclusion, findings from the present study confirm that a higher dietary protein/ 
carbohydrate ratio has appetite regulating effects. Additionally, it shows that 2-AG con-
centrations appear to be an important contributor to appetite related effects of a high- 
protein/moderate-carbohydrate diet, and that PYY may be one of the mediators in this 
increased protein/carbohydrate ratio-induced appetite regulation with an impact on 
reduced hunger perception, after 34 months in the post-obese phase.  
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Figure S2.1: Consort flow diagram of study. 
  
High-protein diet, appetite, gut peptides, and endocannabinoids | CHAPTER 2 
 43 
REFERENCES 
1. World Health Organization. Global Health Observatory (GHO) data. Available online: 
https://www.who.int/gho/ncd/risk_factors/overweight/en/ (accessed on 05/08/2019). 
2. World Health Organization. Global atlas on cardiovascular disease prevention and control; Shanti 
Mendis, P.P., Bo, N., Eds.; World Health Organization: Geneva, Switzerland, 2011; pp 3–18. 
3. Anderson, G.H.; Moore, S.E. Dietary proteins in the regulation of food intake and body weight in 
humans. J. Nutr. 2004, 134, 974S–979S, doi:10.1093/jn/134.4.974S. 
4. Astrup, A. The satiating power of protein—A key to obesity prevention? Am. J. Clin. Nutr 2005, 82, 
1–2, doi:10.1093/ajcn.82.1.1. 
5. Halton, T.L.; Hu, F.B. The effects of high protein diets on thermogenesis, satiety and weight loss: A 
critical review. J. Am. Coll. Nutr. 2004, 23, 373–385. 
6. Paddon-Jones, D.; Westman, E.; Mattes, R.D.; Wolfe, R.R.; Astrup, A.; Westerterp-Plantenga, M. 
Protein, weight management, and satiety. Am. J. Clin. Nutr. 2008, 87, 1558s–1561s, doi:10.1093/ 
ajcn/87.5.1558S. 
7. Reid, M.; Hetherington, M. Relative effects of carbohydrates and protein on satiety—A review of 
methodology. Neurosci. Biobehav. Rev. 1997, 21, 295–308. 
8. Veldhorst, M.A.; Nieuwenhuizen, A.G.; Hochstenbach-Waelen, A.; Westerterp, K.R.; Engelen, M.P.; 
Brummer, R.J.; Deutz, N.E.; Westerterp-Plantenga, M.S. A breakfast with α-lactalbumin, gelatin, or 
gelatin + TRP lowers energy intake at lunch compared with a breakfast with casein, soy, whey, or 
whey-GMP. Clin. Nutr. 2009, 28, 147–155, doi:10.1016/j.clnu.2008.12.003. 
9. Martens, E.A.; Gonnissen, H.K.; Gatta-Cherifi, B.; Janssens, P.L.; Westerterp-Plantenga, M.S. 
Maintenance of energy expenditure on high-protein vs. high-carbohydrate diets at a constant body 
weight may prevent a positive energy balance. Clin. Nutr. 2015, 34, 968–975, doi:10.10 16/j.clnu. 
2014.10.007. 
10. Veldhorst, M.A.; Westerterp, K.R.; Westerterp-Plantenga, M.S. Gluconeogenesis and protein-
induced satiety. Br. J. Nutr. 2012, 107, 595–600, doi:10.1017/S0007114511003254. 
11. Soenen, S.; Martens, E.A.; Hochstenbach-Waelen, A.; Lemmens, S.G.; Westerterp-Plantenga, M.S. 
Normal protein intake is required for body weight loss and weight maintenance, and elevated 
protein intake for additional preservation of resting energy expenditure and fat free mass. J. Nutr. 
2013, 143, 591–596, doi:10.3945/jn.112.167593. 
12. Westerterp-Plantenga, M.S.; Lejeune, M.P.; Nijs, I.; van Ooijen, M.; Kovacs, E.M. High protein intake 
sustains weight maintenance after body weight loss in humans. Int. J. Obes. Relat. Metab. Disord. 
2004, 28, 57–64, doi:10.1038/sj.ijo.0802461. 
13. Lejeune, M.P.; Westerterp, K.R.; Adam, T.C.; Luscombe-Marsh, N.D.; Westerterp-Plantenga, M.S. 
Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate 
metabolism during a high-protein diet and measured in a respiration chamber. Am. J. Clin. Nutr. 
2006, 83, 89–94, doi:10.1093/ ajcn/83.1.89. 
14. Westerterp-Plantenga, M.S.; Rolland, V.; Wilson, S.A.; Westerterp, K.R. Satiety related to 24 h diet-
induced thermogenesis during high protein/carbohydrate vs high fat diets measured in a 
respiration chamber. Eur. J. Clin. Nutr. 1999, 53, 495–502. 
15. Mazier, W.; Saucisse, N.; Gatta-Cherifi, B.; Cota, D. The endocannabinoid system: Pivotal orches-
trator of obesity and metabolic disease. Trends Endocrinol. Metab. 2015, 26, 524–537, doi:10. 
1016/j.tem.2015. 07.007. 
16. Silvestri, C.; Di Marzo, V. The endocannabinoid system in energy homeostasis and the 
etiopathology of metabolic disorders. Cell Metab. 2013, 17, 475–490, doi:10.1016/j.cmet. 2013. 
03.001. 
17. Simon, V.; Cota, D. Mechanisms in endocrinology: Endocannabinoids and metabolism: Past, 
present and future. Eur. J. Endocrinol. 2017, 176, R309–R324, doi:10.1530/EJE-16-1044. 
18. Bluher, M.; Engeli, S.; Kloting, N.; Berndt, J.; Fasshauer, M.; Batkai, S.; Pacher, P.; Schon, M.R.; 
Jordan, J.; Stumvoll, M. Dysregulation of the peripheral and adipose tissue endocannabinoid 
system in human abdominal obesity. Diabetes 2006, 55, 3053–3060, doi:10.2337/db06-0812. 
CHAPTER 2 | High-protein diet, appetite, gut peptides, and endocannabinoids 
 
 44 
19. Cote, M.; Matias, I.; Lemieux, I.; Petrosino, S.; Almeras, N.; Despres, J.P.; Di Marzo, V. Circulating 
endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese 
men. Int. J. Obes. 2007, 31, 692–699, doi:10.1038/sj.ijo.0803539. 
20. Engeli, S.; Lehmann, A.C.; Kaminski, J.; Haas, V.; Janke, J.; Zoerner, A.A.; Luft, F.C.; Tsikas, D.; Jordan, 
J. Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects. 
Obesity 2014, 22, E70–E76, doi:10.1002/oby.20728. 
21. Piomelli, D. A fatty gut feeling. Trends Endocrinol. Metab. 2013, 24, 332–341, doi:10.1016/ j.tem. 
2013.03.001. 
22. Vallee, M.; Vitiello, S.; Bellocchio, L.; Hebert-Chatelain, E.; Monlezun, S.; Martin-Garcia, E.; 
Kasanetz, F.; Baillie, G.L.; Panin, F.; Cathala, A.; et al. Pregnenolone can protect the brain from 
cannabis intoxication. Science 2014, 343, 94–98, doi:10.1126/science.1243985. 
23. Pagotto, U.; Marsicano, G.; Cota, D.; Lutz, B.; Pasquali, R. The emerging role of the endocanna-
binoid system in endocrine regulation and energy balance. Endocr. Rev. 2006, 27, 73–100, doi:10. 
1210/er.2005-0009. 
24. Batterham, R.L.; Heffron, H.; Kapoor, S.; Chivers, J.E.; Chandarana, K.; Herzog, H.; Le Roux, C.W.; 
Thomas, E.L.; Bell, J.D.; Withers, D.J. Critical role for peptide YY in protein-mediated satiation and 
body-weight regulation. Cell Metab. 2006, 4, 223–233, doi:10.1016/j.cmet. 2006.08.001. 
25. Westerterp-Plantenga, M.S.; Lejeune, M.P.; Smeets, A.J.; Luscombe-Marsh, N.D. Sex differences in 
energy homeostatis following a diet relatively high in protein exchanged with carbohydrate, 
assessed in a respiration chamber in humans. Physiol. Behav. 2009, 97, 414–419, doi:10.1016/ 
j.physbeh.2009.03.010. 
26. De Graaf, C.; Blom, W.A.; Smeets, P.A.; Stafleu, A.; Hendriks, H.F. Biomarkers of satiation and 
satiety. Am. J. Clin. Nutr. 2004, 79, 946–961, doi:10.1093/ajcn/79.6.946. 
27. Leidy, H.J.; Armstrong, C.L.; Tang, M.; Mattes, R.D.; Campbell, W.W. The influence of higher protein 
intake and greater eating frequency on appetite control in overweight and obese men. Obesity 
2010, 18, 1725–1732, doi:10.1038/oby.2010.45. 
28. Lemmens, S.G.; Martens, E.A.; Kester, A.D.; Westerterp-Plantenga, M.S. Changes in gut hormone 
and glucose concentrations in relation to hunger and fullness. Am. J. Clin. Nutr. 2011, 94, 717–725, 
doi:10. 3945/ajcn.110.008631. 
29. Fogelholm, M.; Larsen, T.M.; Westerterp-Plantenga, M.; Macdonald, I.; Martinez, J.A.; Boyadjieva, 
N.; Poppitt, S.; Schlicht, W.; Stratton, G.; Sundvall, J.; et al. Preview: Prevention of Diabetes through 
Lifestyle Intervention and Population Studies in Europe and around the World. Design, methods, 
and baseline participant description of an adult cohort enrolled into a three-year randomised 
clinical trial. Nutrients 2017, 9, doi:10.3390/nu9060632. 
30. Drummen, M.; Tischmann, L.; Gatta-Cherifi, B.; Fogelholm, M.; Raben, A.; Adam, T.C.; Westerterp-
Plantenga, M. High versus moderate protein intake reduces adaptive thermogenesis and induces 
a negative energy balance during long-term weight loss maintenance–A preview study. Under Rev.  
31. Schoffelen, P.F.; Westerterp, K.R.; Saris, W.H.; Ten Hoor, F. A dual-respiration chamber system with 
automated calibration. J. Appl. Physiol. 1997, 83, 2064–2072, doi:10.1152/jappl. 1997.83.6.2064. 
32. Weir, J.B. New methods for calculating metabolic rate with special reference to protein 
metabolism. J. Physiol. 1949, 109, 1–9. 
33. Hochstenbach-Waelen, A.; Westerterp-Plantenga, M.S.; Veldhorst, M.A.; Westerterp, K.R. Single-
protein casein and gelatin diets affect energy expenditure similarly but substrate balance and 
appetite differently in adults. J. Nutr. 2009, 139, 2285–2292, doi:10.3945/jn.109. 110403. 
34. Flint, A.; Raben, A.; Blundell, J.E.; Astrup, A. Reproducibility, power and validity of visual analogue 
scales in assessment of appetite sensations in single test meal studies. Int. J. Obes. Relat. Metab. 
Disord. 2000, 24, 38–48. 
35. Matthews, J.N.; Altman, D.G.; Campbell, M.J.; Royston, P. Analysis of serial measurements in 
medical research. BMJ 1990, 300, 230–235. 
36. Gatta-Cherifi, B.; Matias, I.; Vallee, M.; Tabarin, A.; Marsicano, G.; Piazza, P.V.; Cota, D. Simul-
taneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the 
anorexigenic peptide YY in obesity. Int. J. Obes. 2012, 36, 880–885, doi:10.1038/ijo. 2011.165. 
High-protein diet, appetite, gut peptides, and endocannabinoids | CHAPTER 2 
 45 
37. Kingsley, P.J.; Marnett, L.J. LC-MS-MS analysis of neutral eicosanoids. Methods Enzymol. 2007, 433, 
91–112, doi:10.1016/S0076-6879(07)33005-X. 
38. Orskov, C.; Rabenhoj, L.; Wettergren, A.; Kofod, H.; Holst, J.J. Tissue and plasma concentrations of 
amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43, 535–539. 
39. Levy, J.C.; Matthews, D.R.; Hermans, M.P. Correct homeostasis model assessment (HOMA) 
evaluation uses the computer program. Diabetes Care 1998, 21, 2191–2192. 
40. Matias, I.; Gonthier, M.P.; Orlando, P.; Martiadis, V.; De Petrocellis, L.; Cervino, C.; Petrosino, S.; 
Hoareau, L.; Festy, F.; Pasquali, R.; et al. Regulation, function, and dysregulation of endocanna-
binoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J. Clin. 
Endocrinol. Metab. 2006, 91, 3171–3180, doi:10.1210/jc.2005-2679. 
41. Monteleone, P.; Piscitelli, F.; Scognamiglio, P.; Monteleone, A.M.; Canestrelli, B.; Di Marzo, V.; Maj, 
M. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocanna-
binoid 2-arachidonoyl-glycerol in healthy humans: A pilot study. J. Clin. Endocrinol. Metab 2012, 
97, E917–E924, doi:10.1210/jc.2011-3018. 
42. Monteleone, A.M.; Di Marzo, V.; Monteleone, P.; Dalle Grave, R.; Aveta, T.; Ghoch, M.E.; Piscitelli, 
F.; Volpe, U.; Calugi, S.; Maj, M. Responses of peripheral endocannabinoids and endocannabinoid-
related compounds to hedonic eating in obesity. Eur. J. Nutr. 2016, 55, 1799–1805, doi:10.1007/ 
s00394-016-1153-9. 
43. Rigamonti, A.E.; Piscitelli, F.; Aveta, T.; Agosti, F.; De Col, A.; Bini, S.; Cella, S.G.; Di Marzo, V.; 
Sartorio, A. Anticipatory and consummatory effects of (hedonic) chocolate intake are associated 
with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese 
adults. Food Nutr. Res. 2015, 59, 29678, doi:10.3402/fnr.v59.296 78. 
44. DiPatrizio, N.V.; Astarita, G.; Schwartz, G.; Li, X.; Piomelli, D. Endocannabinoid signal in the gut 
controls dietary fat intake. Proc. Natl. Acad. Sci. USA 2011, 108, 12904–12908, doi:10.10 73/pnas. 
1104675108. 
45. Pintus, S.; Murru, E.; Carta, G.; Cordeddu, L.; Batetta, B.; Accossu, S.; Pistis, D.; Uda, S.; Elena Ghiani, 
M.; Mele, M.; et al. Sheep cheese naturally enriched in α-linolenic, conjugated linoleic and vaccenic 
acids improves the lipid profile and reduces anandamide in the plasma of hypercholesterolaemic 
subjects. Br. J. Nutr. 2013, 109, 1453–1462, doi:10.1017/S000711451 2003224. 
46. Hillard, C.J. Circulating endocannabinoids: From whence do they come and where are they going? 
Neuropsychopharmacology 2018, 43, 155–172, doi:10.1038/npp.2017.130. 
47. Rodriguez de Fonseca, F.; Navarro, M.; Gomez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodriguez, 
E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; et al. An anorexic lipid mediator regulated by feeding. 
Nature 2001, 414, 209–212, doi:10.1038/35102582. 
48. Racz, B.; Duskova, M.; Vondra, K.; Sramkova, M.; Hill, M.; Starka, L. Daily profiles of steroid 
hormones and their metabolites related to food intake. Physiol. Res. 2015, 64, S219–S225. 
49. Fu, J.; Gaetani, S.; Oveisi, F.; Lo Verme, J.; Serrano, A.; Rodriguez De Fonseca, F.; Rosengarth, A.; 
Luecke, H.; Di Giacomo, B.; Tarzia, G.; et al. Oleylethanolamide regulates feeding and body weight 
through activation of the nuclear receptor PPAR-α. Nature 2003, 425, 90–93, doi:10.1038/nature 
01921. 
50. Witkamp, R.F. The role of fatty acids and their endocannabinoid-like derivatives in the molecular 
regulation of appetite. Mol. Aspects Med. 2018, 64, 45–67, doi:10.1016/j.mam.20 18.01.002. 
51. Guzman, M.; Lo Verme, J.; Fu, J.; Oveisi, F.; Blazquez, C.; Piomelli, D. Oleoylethanolamide stimulates 
lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α). 
J. Biol. Chem. 2004, 279, 27849–27854, doi:10.1074/jbc.M404087200. 
52. Gatta-Cherifi, B.; Cota, D. Endocannabinoids and metabolic disorders. Handb. Exp. Pharmacol. 
2015, 231, 367–391, doi:10.1007/978-3-319-20825-1_13. 
53. El Khoury, D.; El-Rassi, R.; Azar, S.; Hwalla, N. Postprandial ghrelin and PYY responses of male 
subjects on low carbohydrate meals to varied balancing proportions of proteins and fats. Eur. J. 
Nutr. 2010, 49, 493–500, doi:10.1007/s00394-010-0108-9. 
54. Paddon-Jones, D.; Leidy, H. Dietary protein and muscle in older persons. Curr. Opin. Clin. Nutr. 
Metab. Care 2014, 17, 5–11, doi:10.1097/MCO.0000000000000011. 
CHAPTER 2 | High-protein diet, appetite, gut peptides, and endocannabinoids 
 
 46 
55. Smeets, A.J.; Soenen, S.; Luscombe-Marsh, N.D.; Ueland, O.; Westerterp-Plantenga, M.S. Energy 
expenditure, satiety, and plasma ghrelin, glucagon-like peptide 1, and peptide tyrosine-tyrosine 
concentrations following a single high-protein lunch. J. Nutr. 2008, 138, 698–702, doi:10.1093/jn/ 
138. 4.698. 
56. Raben, A.; Agerholm-Larsen, L.; Flint, A.; Holst, J.J.; Astrup, A. Meals with similar energy densities 
but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and 
substrate metabolism but not on appetite and energy intake. Am. J. Clin. Nutr. 2003, 77, 91–100, 
doi:10.1093/ajcn/ 77.1.91. 
57. Van der Klaauw, A.A.; Keogh, J.M.; Henning, E.; Trowse, V.M.; Dhillo, W.S.; Ghatei, M.A.; Farooqi, 
I.S. High protein intake stimulates postprandial GLP1 and PYY release. Obesity 2013, 21, 1602–
1607, doi:10.1002/oby.20154. 
58. Gennuso, K.P.; Gangnon, R.E.; Thraen-Borowski, K.M.; Colbert, L.H. Dose-response relationships 
between sedentary behaviour and the metabolic syndrome and its components. Diabetologia 
2015, 58, 485–492, doi:10.1007/s00125-014-3453-z. 
59. Henson, J.; Yates, T.; Biddle, S.J.; Edwardson, C.L.; Khunti, K.; Wilmot, E.G.; Gray, L.J.; Gorely, T.; 
Nimmo, M.A.; Davies, M.J. Associations of objectively measured sedentary behaviour and physical 
activity with markers of cardiometabolic health. Diabetologia 2013, 56, 1012–1020, doi:10.1007/ 
s00125-013-2845-9. 
60. Uebanso, T.; Taketani, Y.; Fukaya, M.; Sato, K.; Takei, Y.; Sato, T.; Sawada, N.; Amo, K.; Harada, N.; 
Arai, H.; et al. Hypocaloric high-protein diet improves fatty liver and hypertriglyceridemia in 
sucrose-fed obese rats via two pathways. Am. J. Physiol. Endocrinol. Metab. 2009, 297, E76-84, 
doi:10.1152/ajpendo.00014. 2009. 
61. Margolis, L.M.; Rivas, D.A.; Ezzyat, Y.; Gaffney-Stomberg, E.; Young, A.J.; McClung, J.P.; Fielding, 
R.A.; Pasiakos, S.M. Calorie restricted high protein diets downregulate lipogenesis and lower 
intrahepatic triglyceride concentrations in male rats. Nutrients 2016, 8, 571, doi: 10.3390/ 
nu8090571. 
  

















Role of endocannabinoids in energy balance regulation 
in participants in the post-obese state - a PREVIEW study 
 
 
Mathijs Drummen*, Lea Tischmann*, Blandine Gatta-Cherifi, Daniela Cota, 
Isabelle Matias, Anne Raben, Tanja Adam, Margriet Westerterp-Plantenga 
















Context: Endocannabinoids are suggested to play a role in energy balance regulation.  
Objective: We aimed to investigate associations of endocannabinoid concentrations 
during the day with energy balance and adiposity and interactions with 2 diets differing 
in protein content in participants in the post-obese phase with pre-diabetes.  
Design and participants: Participants (n = 38) were individually fed in energy balance 
with a medium protein (MP: 15:55:30% of energy from Protein:Carbohydrate:Fat) or 
high protein diet (HP: 25:45:30% energy from P:C:F) for 48-hours in a respiration 
chamber.  
Main outcome measures: Associations between energy balance, energy expenditure, RQ 
and endo-cannabinoid concentrations during the day were assessed.  
Results: Plasma-concentrations of anandamide (AEA), oleoylethanolamide (OEA), 
palmitoylethanolamide (PEA), and pregnenolone (PREG) significantly decreased during 
the day. This decrease was inversely related to BMI (AEA) or body-fat (%) (PEA; OEA). 
The lowest RQ value, before lunch, was inversely associated with concentrations of AEA 
and PEA before lunch. AUC of concentrations of AEA, 2-AG, PEA, and OEA were positively 
related to body-fat% (p<0.05). The HP and MP groups showed no differences in 
concentrations of AEA, OEA, PEA, and PREG, but the AUC of 2-arachidonoylglycerol (2-
AG) was significantly higher in the HP vs. the MP group.  
Conclusions: In energy balance, only the endocannabinoid 2-AG changed in relation to 
protein level of the diet, while the endocannabinoid AEA, and endocannabinoid-related 
compounds OEA and PEA reflected the gradual energy intake matching energy 
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INTRODUCTION 
Weight gain and obesity are known risk factors for T2D. The progression of pre-diabetes 
to T2D in individuals with overweight or obesity can be prevented by sustained weight 
loss [1-3]. However, the most effective lifestyle approach to achieve this goal has not 
been clearly defined yet. Therefore, the main objective of the PREVIEW study 
(PREVention of diabetes through lifestyle Intervention and population studies in Europe 
and around the World) [4] was to determine whether a high-protein low-GI (glycaemic 
index) diet was more effective in preventing T2D compared to a moderate protein, 
higher-GI diet for weight maintenance. Another objective was to determine whether a 
shorter, but increased intensity of physical activity (PA) had an additional beneficial 
effect on the outcomes compared with moderate intensity PA.  
The endocannabinoid system (ECS) has been suggested to play a role in the regulation 
of energy balance in humans [5]. The ECS encompasses the endocannabinoid type 
Receptor 1 and 2 (CBRs), the endocannabinoids and the pathways responsible for the 
synthesis and degradation of those ligands [5-7]. Endocannabinoids, of which the most 
studied are arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol 
(2-AG) are polyunsaturated fatty acids produced on demand from membrane phosphor-
lipids to act on CBR in an autocrine or paracrine manner [8]. CB1R is widely distributed 
in the brain and also in peripheral tissues such as adipose tissue, liver, gastro-intestinal 
tract, pancreas and skeletal muscles [5-12], and is suggested to promote obesity[5]. 
Interestingly, by acting both peripherally and centrally and by affecting the actions of 
leptin and insulin, CB1R is a potential therapeutic target against obesity and T2D [7-
10,13-17]. Plasma AEA is positively associated with adiposity [17] and plasma 2-AG is 
associated with ghrelin levels [18], while plasma oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA), two endocannabinoid-related compounds, are suggested 
to act opposite AEA and 2-AG, and may stimulate satiety or energy expenditure [17]. 
Finally, the neurosteroid pregnenolone acts as a signaling specific inhibitor of CB1R, and 
is part of an endogenous negative feedback loop, which decreases the activity of the 
receptor [19,20].   
The endocannabinoids and their related compounds can be modulated by the diet and 
in particular by polyunsaturated fatty acids content [5]. We recently observed that 
postprandial 2-AG concentrations were higher after a diet with increased protein-to-
carbohydrate-ratio, while AEA, OEA, PEA, and PREG concentrations were not affected by 
the macronutrient content of the diet [21]. However, we did not explore possible 
associations between the ECS and energy balance or adiposity in this group of 
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participants. Therefore, the aim of the current study was to investigate possible 
associations of endocannabinoid concentrations during the day with energy balance and 
adiposity in a sub-group of participants with pre-diabetes in the post-obese phase of the 
PREVIEW study.  
 
MATERIALS AND METHODS 
The Medical Ethical Committee of Maastricht University approved the PREVIEW study, 
registered on clinicaltrials.gov with identifier NCT01777893, as well as the respiration 
chamber sub-study. The study was performed in line with the Declaration of Helsinki. All 
volunteers signed written informed consent. 
Participants 
Forty individuals were recruited from the PREVIEW study population at Maastricht 
University in the Netherlands, of whom two dropped out due to lack of time. For the 
general PREVIEW study participants underwent a screening that included anthropo-
metric measurements as described in Fogelholm et al. [4]. Additional exclusion criteria 
for the respiration chamber study were claustrophobia, smoking, and previous cardio-
vascular events.  
Study design 
The PREVIEW study design was composed of a 3 year multinational, randomised trial 
with 4 intervention arms in a 2 x 2 factorial design in eight intervention centres 
(Denmark, Finland, United Kingdom, The Netherlands, Spain, Bulgaria, Australia, and 
New Zealand, with 2326 adults (25-70 y, BMI ≥ 25 kg/m2) with prediabetes as defined by 
the ADA criteria: fasting plasma glucose 5.6-6.9 mmol/L and/or 7.8-11.0 mmol/L at 2 
hours after an oral glucose tolerance test of 75 g glucose, with a fasting plasma glucose 
concentration <7.0 mmol/L [4]. A total of 962 participants completed the 3-year 
intervention starting with a two-month ≥ 8% weight reduction phase using a low-energy 
diet [22] followed by a randomised 34-month weight maintenance phase in one of the 
four treatment arms: High Protein-High Intensity Physical Activity, HP-Medium Intensity 
physical activity, Medium Protein-HI, and MP-MI; (MP: 15:55:30% of energy from 
Protein:Carbohydrate:Fat; HP: 25:45:30% of energy from Protein:Carbohydrate:Fat), 
with the main outcome measures being incidence of T2D over 3 years analysed by diet 
and PA treatment, subsequently according to diet and PA, and secondarily among others 
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changes in body weight, body mass index (BMI), body composition, insulin resistance 
(HOMA-IR) [4]. Close to the last clinical investigation day of the weight maintenance 
period, ~34 months after starting the PREVIEW weight maintenance intervention, 
participants stayed in the respiration chamber for 48 hours. The 38 participants 
participating in the respiration chamber measurements had lost on average 11.1 ± 3.6 
kg (11.9 ± 2.5%; range 8.1% - 18.2%) during the weight loss period.  After the subsequent 
34-month weight maintenance phase the average body weight was still 5.5 ± 6.2 kg 
lower compared to baseline, corresponding with a BMI of 28.9 ± 3.9 kg/m2 and an 
average regain in body weight of 5.6 kg during the weight maintenance phase. There 
were no differences between the two dietary intervention groups, high protein (HP) and 
medium protein (MP), regarding changes in body weight during the PREVIEW 
intervention (Table 3.1). 
Respiration chamber 
Subjects arrived at the Metabolic Research Unit Maastricht (MRUM) research facilities 
in the morning having fasted overnight from 22:00h the night before. The respiration 
chamber session started at 09:30h and stopped 2 days later 09:30h. The respiration 
chamber is an airtight chamber of 14 m3 furnished with a bed, chair, desk with computer, 
TV, telephone, intercom, sink, and toilet. The climate inside the chamber was controlled. 
O2 consumption and CO2 production were continuously measured by open-circuit 
ventilated indirect calorimetry [23]. The room was ventilated with fresh air at a rate of 
70-80 l/min. Flow was measured using electronically modified dry gasmeters (G6, 
gasmeterfabriek Schlumberger, Dordrecht, The Netherlands). The concentrations of O2 
and CO2 were measured with dual pairs of infrared CO2 analyzers (ABB/Hartman&Braun 
Uras, Frankfurt a.M, Germany) and paramagnetic O2 analyzers (Servomex 4100, 
Crowborough, England and ABB/ Hartman&Braun Magnos, Frankfurt a.M, Germany) 
[23]. During each 15-min period, six samples of outgoing air, one sample of fresh air, 
zero gas and calibration gas were measured. The gas samples to be measured were 
selected by a computer that also stored and processed the data [23]. Physical activity 
was continuously measured by use of an ActiSleep+ (ActiGraph LLC, Pensacola, FL) 
accelerometer worn on the hip. Subjects had fixed bed times between 23:30h and 
07:30h. In the daytime, they were not allowed to sleep or to perform exercise. Meals 
were offered at stated times (breakfast: 9:00h, lunch: 13:00h, dinner: 17:45h), and 
subjects were instructed to finish these within 30 min.  
  




Participants received either a moderate protein diet (MP: 15:55:30 from En% protein: 
carbohydrate:fat) or a high protein diet (HP: 25:45:30 En% from protein:carbohydrate: 
fat) corresponding with their dietary intervention instructions during the PREVIEW study 
[4]. The basis of the meals was the same between groups, combined with either 
carbohydrate- or protein-rich food items to keep menus as comparable as possible. The 
diets consisted of commercially available food items and were provided individually in 
energy balance. Individual daily energy requirements (DER) were calculated as the basal 
metabolic rate using the fat-free mass and fat mass [24] multiplied by a physical activity 
level of 1.35 [25]. Daily energy intake was divided over three meals, with breakfast 
containing 20%, and lunch and dinner 40%. During all measurements in the respiration 
chamber, the meals within each condition had the same macronutrient composition. 
Water consumption was allowed ad libitum between the meals; no other foods or 
beverages were available.  
Energy expenditure and respiratory quotient  
Total energy expenditure (TEE) was determined during the 48-h stay in the respiration 
chamber. O2 consumption and CO2 production were used to calculate TEE according to 
the formula of Weir [26]. Energy balance was calculated by subtracting TEE from energy 
intake. Respiratory quotient (RQ) was calculated by dividing CO2 production by O2 
consumption as a measure of substrate oxidation. 
Anthropometric measurements 
Body weight and composition were determined with subjects in the fasted state before 
entering the respiration chamber. Body weight was measured using a calibrated scale 
(Life Measurement Corporation, Inc, Concord, CA, USA). Body composition was 
determined based on body density measured via air-displacement plethysmography 
with the BodPod system (BOD POD, Life Measurement Inc., Concord, CA, USA), utilizing 
Siri’s equation for body density [27]. Height was measured using a wall-mounted 
stadiometer to the nearest 0.1 cm (Seca, model 222, Seca, Hamburg, Germany). 
Metabolic parameters 
On the first and last day of the respiration chamber experiment, fasting blood samples 
were taken from an antecubital vein by venipuncture for the analysis of fasted glucose 
and insulin. In the morning of the second day, a venflon catheter (Becton, Dickinson and 
Company, Franklin Lanes, NY, USA) was placed in the antecubital vein to collect fasted, 
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preprandial and postprandial blood for the analysis of endocannabinoid and related 
compounds. Blood was drawn through an airtight lock in the door, which had a plastic 
‘sleeve’ attached on the participants’ side of the lock. Participants were instructed to put 
their arm in the sleeve and to close it tightly around before the lock was opened. This 
enabled us to draw blood without affecting pressure inside the chamber. Blood samples 
were drawn directly before and 60 minutes after all three meals, with one sample more 
for the endocannabinoids and related compounds analyses at 120 min after dinner. 
Samples were immediately stored on ice, centrifuged for 10 minutes at 1500g at 4°C, 
immediately distributed in aliquots, and stored at -80°C until analysis at the end of the 
study, enabling that all samples from one participant were in the same analytical run.  
Glucose 
Plasma for colorimetric glucose analysis (Roche Diagnostic Systems, Woerden, the 
Netherlands) was collected in sodium fluoride tubes (Becton, Dickinson and Company, 
Franklin Lakes, NY, USA).  
Insulin 
Serum for insulin analysis was collected in serum separator tubes (Becton, Dickinson and 
Company, Franklin Lakes, NY, USA). Serum samples were kept at room temperature for 
30 minutes to allow clotting before centrifugation (10 minutes at 1500g at 4°C). Samples 
were used to analyze fasting and postprandial insulin concentrations with a human 
insulin-specific radioimmunoassay (Linco Research, St Charles, MO, USA). Insulin 
sensitivity was estimated by calculating the homeostasis model assessment for insulin 
resistance (HOMA-IR) [28]. 
Endocannabinoids and endocannabinoid-related compounds 
For endocannabinoid analysis, ice-chilled EDTA tubes (Becton, Dickinson and Company, 
Franklin Lakes, NY, USA) were used. Samples were distributed in aliquots in prepared 
storage cups with 1% PMSF solution (10 mg PMSF in 1 m methanol) and 5% 1N HCL at 
final concentration. The set of different biochemical steps for the extraction, puri-
fication, and quantification of AEA, PEA, OEA and 2-AG from plasma require are 
described previously [12,14,20,29,30]. Subsequently, plasma samples were subjected to 
isotope-dilution liquid chromatography-chemical ionization-tandem mass spectro-
metric analysis. Mass spectral analyses were performed on a TSQ Quantum Access triple 
quadrupole instrument (Thermo-Finnigan) equipped with an APCI source (atmospheric 
pressure chemical ionisation) and operating in positive ion mode [12]. To evaluate 
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between-run precision and reproducibility, quality control samples were prepared by 
directly supplementing a plasma pool control with endocannabinoids and run for each 
batch of samples analyzed. The amounts of AEA, PEA, OEA and 2-AG are expressed as 
pmols per ml of plasma.  
Pregnenolone was extracted by a simple solid-phase extraction method using reverse-
phase C18 columns from EDTA plasma, as described in Vallee et al. [19]. The steroid 
fraction was eluted with methanol (2 ml) into screw-cap test tubes and evaporated to 
dryness at 50°C under a nitrogen stream to prepare for derivatization. Dried methanol 
extracts of plasma and standards were then derivatized by a two-step procedure. The 
formation of pentafluoro-benzyloxime for negative chemical ionization detection was 
followed by trimethylsilyl ether formation for adequate sensitivity. Samples were then 
subjected to isotope-dilution gas chromatography-chemical ionization-tandem mass 
spectrometric analysis. The derivatized samples were injected (1 μl) directly into a 
GCMSMS XLS Ultra Thermo mass spectrometer (Thermo-Finnigan) via an AS3000 II 
autosampler. The instrument was employed in negative ion chemical ionization mode 
and a 15 m Rtx-5Sil MS W/Integra Guard capillary column (Restek, France) with a 0.25 
mm inside diameter and 0.1 μm film thickness was employed for analyte resolution. To 
evaluate between-run precision and reproducibility, quality control samples were 
prepared by directly supplementing a plasma pool control with steroids and run for each 
batch of samples analyzed. The amount of pregnenolone was then expressed as ng per 
ml of plasma. 
Urinary nitrogen 
During both days in the chamber, 24h urine was collected for the analysis of urinary 
nitrogen excretion, as an estimation of protein metabolization (Vario Max, CN-analyzer, 
Elementar Analysesysteme GmbH, Langenselbold, Germany). Urine bottles were 
prepared with 10 ml hydrochloric acid (4 mmol/L) to prevent nitrogen degradation. 
Nitrogen levels were then multiplied with 6.25 to calculate the daily protein intake 
(g/day).  
Statistical analysis   
All statistical tests were performed using SPSS for Macintosh (Version 25; SPSS Inc., 
Chicago, IL, USA). Data are presented as means ± standard deviations (SDs). Significance 
was defined as P<0.05. Normality of the parameters was assessed using the Shapiro-
Wilk test and outliers were detected with the use of box plots in SPSS. In the whole 
group, BMI, AEE and AUCs of activity-induced energy expenditure (AEA), AG and OEA 
Endocannabinoids and energy balance regulation | CHAPTER 3 
 57 
were not normally distributed. In the HP group, protein oxidation, fat oxidation, BMI, 
fat-free mass, body-fat percentage, TEE, and AEE were not normally distributed. In the 
MP group, AUCs of AEA, AG PEA, and OEA also were not normally distributed. For these 
reasons, non-parametric tests were used for the analyses. Differences between both 
groups were calculated using Mann-Whitney U tests. Associations between endocanna-
binoid concentrations were assessed using linear mixed model analysis. Changes in 
endocannabinoids during the day were assessed with repeated-measures ANOVA 
followed by LSD post-test. Repeated measures ANCOVA and Spearman correlation 
analysis was used to assess possible relations between endocannabinoids and 
anthropometric variables, energy balance, substrate oxidation, and insulin resistance.  
 
RESULTS 
Anthropometric variables, HOMA-IR, energy intake and energy expenditure did not 
differ significantly between the HP and MP [31]. Energy balance was significantly lower 
in the HP group compared to MP (p=0.015); respiratory quotient (RQ) also was 
significantly lower in the HP group [31] (Table 3.1). With respect to the endocanna-
binoids and related compounds, AEA concentrations were positively associated with 2-
AG (estimate 0.008; CI: 0.004-0.011; p<0.001), PEA (estimate 0.060; CI: 0.050-0.069; 
p<0.001) and OEA (estimate 0.072; CI: 0.061-0.083; p<0.001) concentrations, assessed 
with linear mixed model analysis (Table 3.1). Likewise, PEA concentrations were 
positively associated with OEA (estimate 0.592; CI: 0.495-0.689; p<0.001) and 2-AG 
(estimate 0.269; CI: 0.081-0.457; p<0.01) and OEA concentrations were positively 
associated with 2-AG (estimate 0.072; CI: 0.061-0.083; p<0.05). PREG concentrations 
were not associated with the other endocannabinoid concentrations. 
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Table 3.1: Anthropometric variables in medium-protein and high-protein groups at baseline, and when 
entering the respiration chamber 
 Baseline Respiration chamber 
 MP (n=18) HP (n=20) p-value MP (n=18) HP (n=20) p-value 
Sex (f/m) 9/9 13/7     
Age (years) 61.5±5.7 59.4±67.7 0.443    
BMI (kg/m2) 31.2±4.1 30.0±3.4 0.553 29.0±3.8 28.9±4.0 0.942 
Fat-free mass (kg) 54.7±11.9 52.7±11.9 0.654 52.5±10.9 50.8±11.3 0.553 
Fat mass (kg) 39.3±9.0 36.5±6.8 0.346 33.9±7.7 34.8±8.8 0.740 
Body-fat (%) 41.9±6.8 41.2±6.3 0.613 39.3±7.4 40.7±7.7 0.593 
HOMA-IR 3.4±2.0 2.9±1.3 0.460 3.8±1.8 3.62±1.34 0.794 
EI (MJ/d)    9.4 ± 1.7 9.3 ± 1.6 0.573 
TEE (MJ/d)    9.2±1.6 9.8±1.7 0.534 
EB, MJ/d    0.2 ± 0.9 -0.5 ± 0.9 0.015 
RQ    0.84 ± 0.02 0.82 ± 0.02 0.004 
Data are presented as mean ± SD. Differences between groups were assessed by means of Mann-
Whitney U tests and the corresponding p-values are shown in the table. Different changes from 
baseline to respiration chamber between groups were assessed by means of analysis of covariance 
(ANCOVA), with baseline values as covariate; there were no significantly different changes between the 
groups. MP = moderate protein; HP = high protein; BMI = body mass index; EI = energy intake;      TEE 
= total energy expenditure; EB = energy balance; RQ = respiratory quotient 
 
The AUC from before breakfast to 120 minutes after the start of dinner, of the plasma 
concentrations of AEA, OEA, PEA, and PREG were not significantly different between the 
two groups. Differently, the AUC of the plasma concentrations of 2-AG was significantly 
higher in the HP compared to the MP group (4351 ± 1616 vs. 3368 ± 1552, F=4.67, 
p<0.05) [21]. There were no significant group*time interactions between the groups, 
assessed with repeated measures ANOVA (Figure 3.1). Therefore, the two groups have 
been pulled together for further analyses.  
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Figure 3.1: Endocannabinoid concentrations during the day in the medium protein (MP) and high 
protein (HP) group. AEA = anandamide; 2-AG = 2-arachidonoylglycerol; PEA = palmitoylethanolamide 
OEA = oleoylethanolamide; PREG = pregnenolone. 
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In the whole group, body-fat% was a significant predictor for AEA (p<0.01; ηp2=0.19), 2-
AG (p<0.05; ηp2=0.13), PEA (p<0.05; ηp2=0.14) and OEA (p<0.05; ηp2=0.16) concen-
trations, assessed with repeated measured ANCOVA. These results were also reflected 
by significant positive associations between the AUC of the endocannabinoid concen-
trations of AEA (r=0.43), 2-AG (r=0.37), PEA (r=0.34), and OEA (r=0.40) and body-fat% 
(p<0.05), indicating that those subjects with a higher body-fat% had higher levels of 
these endocannabinoids and related compounds. Differently, the AUC of PREG 
concentrations was not related to body-fat%. We also assessed associations between 
TEE and endocannabinoid concentrations using repeated measures ANCOVA, correcting 
for FFM. TEE was a positive contributor to AEA (p<0.05; ηp2=0.17) and OEA (p<0.05; 
ηp2=0.12) concentrations. No relationships appeared with energy balance or HOMA-IR 
for any of the endocannabinoid concentrations and related compounds. 
Interestingly, in the whole group the plasma concentrations of AEA, PEA, OEA and PREG 
were the highest in the fasted state and decreased significantly during the day (Table 
3.2), without showing any clear meal associated pattern. The change in these 
concentrations from fasting to 120 min after dinner was inversely related to BMI (AEA: 
r=-0.33) or body-fat% (PEA: -0.37; OEA: -0.38) (Figure 3.2); changes in PREG concen-
trations were not related to anthropometric values. Moreover, the RQ before the lunch 
appeared to be the minimum RQ value over 24h, namely RQ=0.71±0.04. This RQ value 
was inversely associated with concentrations of AEA (r=-0.39; p=0.016) and PEA              
(r=-0.34; p=0.04) before lunch (Figure 3.3). 
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Figure 3.2: Associations of change in endocannabinoid concentration over the day and BMI (kg/m2) and 
body-fat % assessed with Spearman’s correlation analysis. AEA = anandamide; PEA = palmitoylethanol-
amide; OEA = oleoylethanolamide. 
 
Endocannabinoids and energy balance regulation | CHAPTER 3 
 63 
 
Figure 3.3: Associations of endocannabinoid concentration and respiratory quotient before the lunch 
assessed with Spearman’s correlation analysis. AEA = anandamide; PEA = palmitoylethanolamide. 
 
Lastly, we have assessed the relationship between change in BMI or body-fat % prior to 
the respiration chamber measurements and endocannabinoid concentrations during 
the day. Changes in BMI (%) positively predicted 2-AG concentrations (ηp2= 0.142 
p<0.05), but no other endocannabinoid concentrations.  
Furthermore, there were no associations between body-fat% and endocannabinoid 
concentrations or between changes in BMI% or body-fat% and changes in endocanna-
binoid concentrations during the day. 
 
 




The present 48h respiration chamber study, during which PREVIEW-participants in the 
post-obese phase were individually fed in energy balance, and in controlled 
macronutrient proportions, offered an excellent opportunity to investigate the 
concentrations of endocannabinoids and related compounds throughout the day, the 
changes thereof, and the possible interaction with energy balance. While we did not find 
associations between the endocannabinoid concentrations and energy balance or 
adiposity, reductions in the concentrations of AEA, OEA, PEA, and PREG during the day 
were inversely related with BMI and body-fat%. 
In the whole group of participants, we found statistically significant decreases in 
concentrations from fasting to 120 min after dinner in AEA, OEA, PEA, and PREG. This 
may suggest that these endocannabinoids respond to a gradual energy supply to meet 
energy balance during the day. This is also in line with the finding that AEA and OEA were 
positively associated, corrected for FFM. Participants with a higher energy turn-over 
presented with higher concentrations of AEA and OEA, which may again be an effort to 
meet energy balance during the day. This was further underscored by the lowest RQ 
during the day, before the lunch, being inversely associated with concentrations of AEA 
and PEA before lunch. The significant decrease of AEA, OEA, PEA, and PREG may point 
toward a circadian rhythm in the secretion of these compounds, as was suggested 
before [32]. OEA and PEA changed in the same direction as AEA, which can be explained 
by the fact that these compounds, although physiologically playing different roles, are 
synthesized along the same intracellular pathways [9]. Again, this may be due to the 
controlled study design of feeding participants in energy balance, which does not imply 
strong feelings of craving or fullness.  
Moreover, the changes in concentrations of AEA, OEA and PEA were inversely related to 
BMI (AEA) and body-fat% (PEA, OEA). This may indicate that those with a lower BMI or 
fat mass presented with a stronger energy balance regulation compared to those with a 
higher BMI or fat mass, who could easily live on their reserves for a longer period of 
time. The lack of a relationship of pregnenolone concentrations with anthropometric 
measurements underscores the different functionality of pregnenolone inhibiting the 
CB1R [19,20], which likely only takes place upon important and sustained activation of 
CB1R.  
With respect to the effect of diets with different protein and carbohydrate compositions 
on endocannabinoid concentrations and interactions with energy balance, we observed 
no statistically significant differences in AEA, OEA, PEA and PREG concentrations 
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between the 2 diets used in the study. Only the AUC of 2-AG was statistically significantly 
different between the diets, in that it was higher in the HP diet group compared to the 
MP diet group [21]. Moreover, the concentrations of AEA, 2-AG, OEA, PEA and PREG 
were not associated with energy balance, energy expenditure, or insulin sensitivity, 
independently of diet group. This is in contrast with previous studies that underscore 
the hypothesis of AEA being an orexigenic factor showing a pattern of changes in 
circulating AEA concentrations around meals [29,33,34]. AEA concentrations have been 
observed to be increased before meals in participants with normal weight and with 
obesity [29] and to be decreased after food consumption [11,33,34], independently of 
the hedonic value of the meal in participants with normal weight [35]. Furthermore, it 
was observed that the endocannabinoids may affect energy balance in that AEA and 2-
AG would promote energy intake and might be inhibited by PREG, while OEA and PEA 
would promote satiety or energy expenditure [17-20,36]. Moreover, AEA has been 
suggested to affect energy expenditure by mediating the effect of skeletal muscle 
sphingomyelins [37]. Finally, associations of peripheral endocannabinoids with energy 
expenditure in native Americans have been reported [38]. That we did not observe any 
of those effects may be due to the controlled design of the study, with participants being 
fed to their individual energy balance, and having to finish the food that was offered to 
them, without the possibility of hedonic eating or overeating [33,34]. To our knowledge, 
this is the first study to investigate the relationship between endocannabinoid excursion 
during the day, adiposity, and energy metabolism in a controlled study design during the 
post-obese phase, while fed in energy balance. 
Interestingly, we found a positive relation between the degree of weight loss prior to 
the respiration chamber measurements and 2-AG concentrations during the respiration 
chamber, with higher weight loss being associated with lower 2-AG concentrations 
possibly due to a reduction in ghrelin and hunger [18]. Moreover, in the present 
conditions we did not observe any associations with insulin sensitivity, which have been 
reported before [15], although our participants still presented with the characteristics 
of pre-diabetes. Being previously obese, participants were in a post-obese state on 
average, when being assessed in the respiration chamber. While previous literature has 
shown links between circulating endocannabinoids and metabolic parameters in obese 
subjects, it is unclear how these relationships hold after people have lost weight. This 
relationship may depend on the timing of the measurements, i.e. during weight loss or 
short-term after weight loss when in fact the effect during negative energy balance is 
measured, or long-term after weight loss when energy balance has been established 
again. Studies investigating changes in endocannabinoid concentrations after bariatric 
surgery induced weight loss found an increase in AEA but not 2-AG levels after 2 months 
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after surgery [39] and a reduction in levels of 2-AG and AEA at 12 months after surgery 
[40]. A 16-week very low calorie diet led to a reduction in AEA levels, but not 2-AG levels 
[41] and a 1-year lifestyle programme including healthy eating and physical eating led to 
a reduction in both, 2-AG and AEA [42]. Given the rather substantial weight change after 
surgery, our study adds to the body of literature by assessing the post obese individuals 
while being fed in energy balance. 
We need to point out a limitation regarding the design of the current study. We would 
have preferred to include the respiration chamber and endocannabinoid measurements 
at the start of the PREVIEW study as well. However, this was not feasible without putting 
too much strain on the participants. Furthermore, it has to be considered that the 
relationships between endocannabinoid concentrations and body-fat% and RQ that 
were reported in the present study, would not survive correction for multiple 
comparisons (e.g., Bonferroni correction). Therefore, the findings of the present study 
need to be confirmed in a larger group of participants. Even though meals were obtained 
from general supermarkets and were provided as close as possible to free living 
conditions, they may have slightly differed from consumed food in the home condition 
of the participants. Therefore, we cannot rule out that interactions between the diet 
group in the respiration chamber and in the free-living condition may have masked diet-
specific effects. However, a possible interaction does not affect the main conclusions. 
Taken together, we did not observe differences in the concentrations of endocanna-
binoids and related compounds due to differences in macronutrient compositions, 
except for 2-AG which we interpreted as possibly related to a higher satiety. We did 
observe a significant decrease of AEA, OEA and PEA concentrations during the day, 
probably indicating the gradual energy supply over the day. This decrease in 
endocannabinoid concentrations was inversely related to BMI or body-fat%, suggesting 
a stronger energy balance regulation in those with a lower adiposity. In conclusion, in 
energy balance, only the endocannabinoid 2-AG changed in relation with protein level 
in the diet, while the endocannabinoid AEA, and endocannabinoid-related compounds 
OEA and PEA reflected the gradual energy intake matching energy expenditure over the 
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Background: An unfavorable lipid profile and being overweight are known mediators in 
the development of cardiovascular disease (CVD) risk. The effect of diet, particularly high 
in protein, remains under discussion.  
Objective: Therefore, this study examines the effects of a high-protein (HP) diet on 
cardiometabolic health and vascular function (i.e., endothelial function, arterial stiffness, 
and retinal microvascular structure), and the possible association with plasma 
endocannabinoids and endocannabinoid-related compounds in overweight participants.  
Design: Thirty-eight participants (64.5 ± 5.9 (mean ± SD) years; body mass index (BMI) 
28.9 ± 4.0 kg/m2) were measured for 48 h in a respiration chamber after body-weight 
maintenance for approximately 34 months following weight reduction. Diets with either 
a HP (n = 20) or moderate protein (MP; n = 18) content (25%/45%/30% vs. 15%/55%/ 
30% protein/carbohydrate/fat) were provided in energy balance. Validated markers for 
cardiometabolic health (i.e., office blood pressure (BP) and serum lipoprotein concen-
trations) and vascular function (i.e., brachial artery flow-mediated vasodilation, pulse 
wave analysis and velocity, and retinal microvascular calibers) were measured before 
and after those 48 h. Additionally, 24 h ambulatory BP, plasma anandamide (AEA), 2-
arachidonoylglycerol (2-AG), oleoylethanolamide (OEA), palmitoylethanol-amide (PEA), 
and pregnenolone (PREG) were analyzed throughout the day.  
Results: Office and ambulatory BP, serum lipoprotein concentrations, and vascular 
function markers were not different between the groups. Only heart rate (HR) was 
higher in the HP group. HR was positively associated with OEA, while OEA and PEA were 
also positively associated with total cholesterol (TC) and low-density lipoprotein (LDL) 
cholesterol concentrations. Vascular function markers were not associated with endo-
cannabinoids (or endocannabinoid-related substances).  
Conclusion: In conclusion, the HP diet did not affect cardiometabolic health and vascular 
function in overweight participants after completing a weight-loss intervention. 
Furthermore, our data indicate a possible association between OEA and PEA with TC and 
LDL cholesterol.  
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INTRODUCTION 
Cardiovascular disease (CVD) is the most common cause of death worldwide [1]. Well-
known mediators in the development of vascular damage and CVD are an unfavorable 
serum lipid profile and being overweight [2]. Whilst an unhealthy diet (e.g., high in salt 
and saturated fat) is known as a risk factor for the development of CVD [2], the effect of 
macronutrients, in particular the effect of dietary protein in general remains under 
discussion [3]. Reviews on the relationships between longer-term protein intakes with 
CVD [4], serum lipids, and blood pressure (BP) [5] are however inconclusive and more 
research is warranted in this field [6–8]. In addition to diet, it has recently been 
suggested that the endocannabinoid system (ECS) plays a role in the regulation of 
cardiometabolic health and vascular function. The ECS consists of three components: (1) 
the cannabinoid receptors (CB1 and CB2), (2) enzymes responsible for the metabo-
lization of ligands, and (3) endogenous ligands. Those ligands are endocannabinoids like 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and endocannabinoid-related 
compounds like oleoylethanolamide (OEA), palmitoylethanol-amide (PEA), and 
pregnenolone (PREG). 
AEA and 2-AG may affect factors directly related to cardiovascular health [9–11] 
including the regulation of blood pressure [11] and may exert beneficial vasoactive 
properties [10,12]. More specifically, a positive correlation of 2-AG with body mass index 
(BMI) and body fat percentage, with an unfavorable lipid profile, and a higher glycemic 
response has been found [9]. For AEA, results are more conflicting, as plasma concen-
trations vary considerably among studies [9]. Treatment with CB1 antagonists improved 
plasma lipid profiles [13–15], and reduced blood pressure in humans [11], but was also 
associated with adverse events including psychological problems [16]. Data on the 
impact of diet on the ECS system are limited, but it may be affected by fat intake [17]. 
Recently, however, we found a higher dietary protein intake had an enhancing effect on 
plasma 2-AG concentrations [18]. 
Currently, human intervention data on the role of the ECS in protein-induced effects on 
cardiometabolic health and vascular function are limited. Related to our findings of an 
increasing effect of protein intake on plasma 2-AG concentrations [18], we propose that 
the ECS is a possible route of action by which dietary protein affects cardiometabolic risk 
and vascular function markers. Therefore, this study aims to assess the effects of a high-
protein (HP) versus a moderate-protein (MP) diet in overweight participants on 
validated markers for cardiometabolic health and vascular function. As a secondary 
objective, this study examines a possible association of those markers for cardio-
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metabolic health and vascular function with circulating endocannabinoids and related 
compounds concentrations. This study was designed as a substudy of the PREVIEW 
intervention study [19]. 
 
MATERIALS AND METHODS 
The study was performed according to the Declaration of Helsinki and approved by the 
Maastricht University Medical Centre’s Medical Research Ethics Committee (METC). The 
PREVIEW study was registered on 29 January 2013 at ClinicalTrials.gov (NCT01777893). 
Written informed consent for participation was collected from all participants prior to 
the study. The substudy was performed from February 2017 until February 2018 in 
Maastricht, The Netherlands. 
Study design 
The present study was set up as a substudy to PREVIEW, a study assessing the prevention 
of diabetes through lifestyle intervention and population studies in Europe and around 
the world. The PREVIEW study was funded through the European Union (EU) 7th 
Framework Program (grant agreement no. 31205) [19]. Detailed information on the 
PREVIEW intervention and on the substudy has been published [18,19]. In brief, the 
PREVIEW intervention started with 8 weeks of weight loss, followed by 34 months of a 
randomized intervention with either a moderate-protein (MP), moderate-glycemic 
index (GI) or a high-protein (HP), low-GI diet, combined with either moderate- or high-
intensity physical activity in a parallel design. After 34 months, a subgroup of 40 
participants from the PREVIEW cohort [19] of Maastricht University in the Netherlands 
was recruited for the respiration chamber experiment [18]. Two participants of the 40 
recruited dropped out due to a lack of time. Inclusion criteria for PREVIEW were 
previously described [19]. In short, participants were aged between 25 and 70 years and 
had to be overweight (BMI >25 kg/m2). Adults with prediabetes were included, defined 
as a fasting plasma glucose concentration between 5.6 and 6.9 mmol/L and/or a 2 h 
plasma glucose between 7.8 and 11.0 mmol/L following an oral glucose tolerance test 
(OGTT) [19]. 
For the substudy, participants arrived fasted (from 10:00 p.m. the evening before) at the 
research facilities in the Metabolic Research Unit Maastricht. At baseline, fasted blood 
samples were drawn, and anthropometric measurements included weight and body 
composition (BOD POD, Life Measurement Inc., Concord, CA, USA). Vascular function 
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markers were assessed prior to and after their 48-h stay in the respiration chamber (in 
the following the terms pre- and post-respiration chamber will be used to refer to these 
measurement time points). In the respiration chambers energy expenditure was 
assessed by means of a continuous O2 and CO2 concentration measurement. The open-
circuit indirect calorimetry was possible due to the airtight set up of the rooms with 
controlled climate and continuous fresh air ventilation [20]. Participants received three 
standardized meals per day, either with moderate-protein (MP: 15/55/30% energy from 
protein/carbohydrate/fat, respectively) or high-protein (HP: 25/45/30% energy from 
protein/carbohydrate/fat, respectively) content, which were in accordance with 
participants’ assigned intervention group during the PREVIEW study. Physical activity 
intensity based on the intervention was evenly spread (n = 8 high intensity and n = 12 
moderate intensity in the HP group and n = 8 high intensity and n = 10 moderate 
intensity in the MP group) for the respiration chamber study. Fat content and quality 
were comparable between the groups. At the start of the substudy, participants did not 
significantly differ in their habitual dietary protein intake. All meals were provided 
through the laboratory and the investigators to reach energy balance tailored to 
individual energy requirements [18]. 
Cardiometabolic risk markers 
Ambulatory and office blood pressure 
Ambulatory BP (AMBP) was measured at regular intervals during the 48 h in the 
respiration chamber with a portable BP monitor (Mobil-O-Graph® NG; APC 
Cardiovascular, Hartford, UK) as explained by Joris and colleagues [21]. In short, AMBP 
was measured in 15 min intervals during daytime (7:30 a.m.–11:30 p.m.) and in 30 min 
intervals during nighttime (11:30 p.m.–7:30 a.m.). The first measurement was discarded 
from the analysis and mean values for systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), heart rate (HR), mean arterial pressure (MAP), and pulse pressure (PP) 
were calculated for the total 48 h period, as well as for daytime (7:30 a.m.–11:30 p.m.) 
and nighttime (11:30 p.m.–7:30 a.m.) separately. Additionally, systolic and diastolic 
dipping during the night were calculated as described [21]. 
Office BP was measured (Microlife, Wildnau, Switzerland) in supine position. The mean 
SBP and DBP were assessed, while the mean arterial pressure (MAP) and pulse pressure 
(PP) were calculated afterwards using the following formulae: MAP = 1/3 × SBP + 2/3 × 
DBP and PP = SBP − DBP. 
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Serum lipids and lipoproteins 
Fasting blood samples were taken in tubes equipped for serum separation (Becton, 
Dickinson and Company, Franklin Lakes, NY, USA) by venipuncture from the antecubital 
vein at pre- and post- respiration chamber time points. Clotting was allowed for 30 min 
at room temperature before centrifugation (10 min, 1500× g, 4 °C). Aliquots were stored 
at −80 °C until analysis. Serum aliquots were used for the analysis of total cholesterol 
(TC) (CHOD-PAP method, Roche Diagnostics System, Mannheim, Germany), high-density 
lipoprotein (HDL) cholesterol (precipitation method followed by CHOD-PAP method; 
Roche Diagnostics System), and triacylglycerol (TAG; GPO Trinder; Sigma-Aldrich Corp., 
St. Louis, MO, USA). Low-density lipoprotein (LDL) cholesterol concentrations were 
calculated using the Friedewald formula [22]. 
Vascular function measurements 
Vascular function measurements were performed in a fasted state at pre- and post-
respiration chamber time points, in a quiet and darkened room. The room was 
temperature controlled at 24 °C. Measurements were performed in supine position after 
an acclimatization period of at least 15 min. Detailed information has been described 
before by Joris et al. [23]. In brief, endothelial function was measured by brachial artery 
flow-mediated vasodilation (FMD) by use of ultrasound echography (Sonos 5500, 
Hewlett-Packard, Palo Alto, CA, USA). Pulse wave analysis (PWA; cAIxHR75) and carotid-
to-femoral pulse wave velocity (PWVc–f) measurements were performed in triplicate 
with a tonometer (SphygmoCor v9; AtCor Medical, West Ryde, Australia) to assess 
arterial stiffness, and retinal vascular images were obtained to determine microvascular 
calibers using a nonmydriatic retinal camera (Topcon TRC-NW-300; Topcon Co., Tokyo, 
Japan). 
Endocannabinoids and endocannabinoid-related compounds 
Plasma from EDTA tubes (Becton, Dickinson and Company, Franklin Lakes, NY, USA) were 
used for the analysis of AEA, PEA, OEA, 2-AG, and PREG as described [18]. Vacutainers 
contained 1% phenylmethylsulfonyl fluoride (PMSF) solution (10 mg PMSF in 1 mL 
methanol) and 5% 1N hydrochloric acid at final concentration. EDTA tubes and syringes 
for the blood sampling were ice chilled. After centrifugation (10 min, 1500 g, 4 °C) 
plasma was aliquoted and snap frozen immediately. AEA, 2-AG, OEA, and PEA were 
quantified with mass spectral analyses 5LC-M/MS (TSQ Quantum Access triple 
quadrupole instrument; Thermo-Finnigan, San Jose, CA, USA) [9,24,25] while PREG was 
quantified with GC-MS/MS (gas chromatography-tandem mass spectrometer) XLS Ultra 
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Thermo mass spectrometer (Thermo-Finnigan, San Jose, CA, USA) via an AS3000 II 
autosampler [26]. Blood samples for endocannabinoid analysis were drawn directly 
before and 60 min after all three meals with one additional sample at 120 min after 
dinner.  
Statistical analyses 
Sample size was powered based on the primary outcome energy expenditure [27]. SPSS 
version 25 was used for statistical analyses (SPSS for Macintosh; SPSS Inc., Chicago, IL, 
USA). Data are presented as means ± standard deviation (SD). Data were log-
transformed if not normally distributed as tested by the Shapiro–Wilk test. The 
trapezoidal method was used to calculate the area under the curve (AUC) for 
endocannabinoids and related substances [28] for the whole day. Differences at baseline 
between groups were determined by ANOVA and the treatment effect was calculated 
by an ANCOVA where the baseline variable was used as a covariate. Partial correlations 
with body fat % as covariate were used to assess associations between cardiovascular 




Participant characteristics prior to the respiration chamber stay were previously 
described [18]. In brief, no differences in age, BMI, body composition, and C-reactive 
protein (CRP) were found between the MP and HP intervention groups prior to the 
respiration chamber experiment (Table S4.1). 
Cardiometabolic risk markers 
Office and ambulatory blood pressure 
Mean 24 h, mean daytime, or mean nighttime ambulatory SBP, DBP, PP, and MAP were 
not different between intervention groups. However, 24 h and daytime HR were 
significantly higher in the HP group (both p < 0.05). No differences in nighttime SBP or 
DBP dipping were observed (Table 4.1). Similar results were observed for the office 
blood pressure measurements (Table S4.2). 
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Table 4.1: Ambulatory blood pressure measurements during 48 h of the respiration chamber stay with 
a moderate- or high-protein dietary diet. 
 
Moderate Protein 
(n = 18) 
High Protein 
(n = 20) 
24 h SBP (mmHg) 133 ± 12 131 ± 12 
 DBP (mmHg) 82 ± 8 79 ± 7 
 MAP (mmHg) 106 ± 9 103 ± 9 
 PP (mmHg) 51 ± 9 52 ± 9 
 HR (bpm) 62 ± 9 67 ± 5* 
    
Daytime SBP (mmHg) 139 ± 13 136 ± 13 
 DBP (mmHg) 86 ± 9 83 ± 8 
 MAP (mmHg) 111 ± 10 107 ± 9 
 PP (mmHg) 53 ± 10 53 ± 9 
 HR (bpm) 63 ± 9 69 ± 5* 
    
Nighttime SBP (mmHg) 116 ± 13 117 ± 15 
 DBP (mmHg) 68 ± 6 67 ± 8 
 MAP (mmHg) 90 ± 9 90 ± 11 
 PP (mmHg) 48 ± 10 48 ± 7 
 HR (bpm) 58 ± 8 61 ± 7 
    
Dipping SBP (%) 16 ± 9 16 ± 3 
 DBP (%) 21 ± 6 19 ± 7 
* p < 0.05. Values are presented as mean ± SD. A one-way ANOVA was used to calculate differences 
between the groups. SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean arterial 
pressure; PP = pulse pressure; HR = heart rate; bpm = beats per minute.    
 
Serum lipids and lipoproteins 
Effects of the high- and moderate-protein diet in the respiration chamber on metabolic 
risk markers are presented in Table 4.2. Total cholesterol and LDL cholesterol 
concentrations were comparable between intervention groups at pre- and post-
respiration chamber measurements and did not change in any of the groups. Changes 
in HDL cholesterol concentrations were not different between the MP and HP inter-
vention group. The total cholesterol/HDL cholesterol ratio was not different between 
groups (Table 4.2). As described before, changes in TAG were less pronounced in the HP 
group [18]. 
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Table 4.2: Metabolic risk markers at pre- and post-respiration chamber time points with a moderate- 
and high-protein diet. 
 
Moderate Protein 
(n = 18) 
High Protein 
(n = 20) 
Treatment 
Effect 
 Pre1 Post1 Pre1 Post1 Difference in Change2 
Total cholesterol (mmol/L) 5.6 ± 1.1 5.6 ± 1.0 5.6 ± 1.0 5.5 ± 1.0 −0.1 (−0.3; 0.2) 
HDL cholesterol (mmol/L) 1.4 ± 0.3 1.3 ± 0.2 1.5 ± 0.3 1.4 ± 0.3 0.0 (−0.1; 0.1) 
LDL cholesterol (mmol/L) 3.5 ± 0.9 3.4 ± 0.8 3.4 ± 0.9 3.3 ± 0.8 0.0 (−0.2; 0.2) 
Total cholesterol/HDL 
cholesterol ratio 4.0 ± 0.9 4.4 ± 1.1 3.6 ± 0.7 3.9 ± 0.7 −0.1 (−0.3; 0.1) 
1Values are means ± SD; 2Treatment effects (95% confidence interval (CI)) were obtained from a one-
factor ANCOVA with baseline value as covariate. HDL = high-density lipoprotein; LDL = low-density lipo-
protein. 
 
Endothelial function, arterial stiffness, and retinal microvascular structure 
FMD, an important marker reflecting vascular endothelial function, was not different 
between the groups and was also similar comparing pre- and post-respiration chamber 
time points, as presented in Table 4.3. Similar results were observed for markers of 
arterial stiffness, the central augmentation index adjusted for heart rate (cAIxHR75), and 
for PWVc-f. Finally, retinal microvascular calibers and the arteriolar-to-venular ratio did 
not differ between treatment groups and did not change (Table 4.3). 
Endocannabinoids and endocannabinoid-related compounds 
As previously described [18], plasma 2-AG concentrations increased after meals and 
were generally higher in the HP condition. AEA, OEA, PEA, and PREG decreased 
throughout the day and were not affected by dietary protein intake [18]. AEA, 2-AG, 
OEA, and PEA were all positively associated with body fat percentage [29].  
Plasma OEA concentrations were positively associated with 24 h and daily AMBP HR 
(Figure 4.1), total cholesterol, and LDL cholesterol (Figure 4.1), while PEA was positively 
associated with total cholesterol, LDL cholesterol, and HDL cholesterol (Figure 4.1). As 
there were no differences in PEA and OEA between the two intervention groups, the 
associations are presented for the whole group. In contrast, 2-AG, AEA, and PREG 
showed no associations with cardiometabolic risk or vascular function markers. 
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In the current study the effects of a high-protein diet on cardiometabolic health and 
vascular function markers were examined in overweight participants. The study 
indicates that a diet with a higher protein content did not affect markers for metabolic 
health and vascular function, as serum lipoprotein concentrations and BP or markers for 
endothelial function, respectively. Only HR was higher with a HP diet. As a secondary 
aim, possible associations of markers for cardiometabolic health and vascular function 
with endocannabinoids and endocannabinoid-related compounds were examined. 
Here, the endocannabinoid-related compounds OEA and PEA were positively associated 
with cardiometabolic risk markers, such as serum cholesterol concentrations and HR, 
independent of protein intake. 
In general, most of the individuals in the current study can be classified as hypertensive 
according to the 2018 European Society of Cardiology/ European Society of Hyper-
tension (ESC/ESH) guidelines [30]. In a previous study, a HP diet reduced DBP compared 
to a normal protein diet, when combined with weight loss [31]. In the present study, no 
effects on BP were found comparing the two protein intervention groups. However, 
studies reporting effects of dietary protein on the regulation of blood pressure are con-
flicting [32,33], possibly due to the type of protein, whether it originates from plants or 
animals, or due to a specific amino acid composition. In the context of the amino acid 
composition, sulfur-containing amino acids like cysteine or methionine may raise blood 
pressure, while amino acids involved in gluconeogenesis may have lowering effects on 
blood pressure [34]. In the current study, a mixed-protein diet was used without any 
focus on the origin of protein or on a particular amino acid composition, which may 
explain the lack of effect on BP. 
In contrast, HR was higher with a higher dietary protein content. This may be an expla-
nation for the protein-induced effects on energy balance as discussed previously [27]. A 
positive association between HR and energy expenditure has been demonstrated and 
employed to develop a prediction model for energy expenditure in free living conditions 
based on heart rate [35]. 
The link between endocannabinoids and blood pressure is still unclear and clinical 
studies are limited. However, pharmacological blockade of the CB1 receptor reduced BP 
in humans [13,14], suggesting a possible relationship of the ECS with blood pressure. 
The fact that the relationship could not be confirmed in the present study may be 
explained by the different study set up, as previous studies focused on the deactivation 
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of the receptor instead of investigating the relationship between BP and plasma 
endocannabinoid concentrations. 
In our study, we observed a positive association between the endocannabinoid-related 
compound OEA with HR. A possible connection of cannabis use and HR was previously 
found, in which tetrahydrocannabinol (THC), an active compound of cannabis, increased 
HR without concomitant changes in BP [36]. As THC interacts to CB1, in contrast to OEA 
which acts CB1-independent, we suggest that effects on heart rate could also originate 
from a CB1 receptor independent mechanism. 
Next to BP, metabolic risk markers were measured. No statistically significant differences 
in total cholesterol, LDL cholesterol, and HDL cholesterol concentrations were observed 
between the two protein intervention groups, possibly due to the short duration of the 
respiration chamber experiment. In addition, the total cholesterol/HDL cholesterol ratio 
did not differ. So far, the literature is inconclusive with regard to lipoprotein metabolism 
and protein intake. While beneficial effects on serum lipoprotein concentrations, 
independent of the amount of dietary fat intake, were only present in healthy, young 
individuals with a high-protein diet [37], studies in overweight and obese participants 
did not show a clear effect of a mixed-protein diet on serum lipoprotein concentrations 
[31,38,39]. In contrast, a meta-analysis investigating the effects of soy protein on 
lipoprotein concentrations indicated a reduction in LDL cholesterol [40,41], supporting 
the idea that the type of protein may be of great importance. 
The ECS has been discussed to play a role in lipid metabolism [42], dyslipidemia, and 
lipogenesis [43]. In the current study, total cholesterol and LDL cholesterol concentra-
tions were associated with OEA and PEA, independent of protein intake, suggesting a 
possible regulatory role for OEA and PEA in lipidemia. Meanwhile, 2-AG, AEA, and PREG 
were not related to any of the circulating risk markers. 
Generally, OEA concentrations in saliva are higher in obese individuals compared to lean 
individuals [44] and associated with visceral fat content [45]. Animal data indicated a 
cholesterol lowering effect of OEA treatment [46]. While the animal data are not in 
agreement with the outcome of the current study, the ECS in animals may not 
necessarily be representative of the human ECS. PEA, in contrast, has been positively 
associated with total cholesterol and LDL cholesterol concentrations [47]. Interestingly, 
associations of PEA with HDL cholesterol were also positive in the current study whilst 
inverse associations were demonstrated previously [14]. The literature showed a 
positive association of 2-AG with TAG and a negative association with HDL cholesterol 
[9], while no associations were found in the current study. 
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No effects of a diet with a higher protein content were observed on vascular function 
which is in line with previous literature [48]. With regard to vascular function, most of 
the studies focused on the effect of specific proteins like whey or dairy products instead 
of a whole-protein approach. Whey protein intake was shown to improve FMD [49], 
whereas there was no effect of dairy intake on FMD and other markers for endothelial 
function [50,51], and no effect was reported by a mixed-protein approach [48]. Arterial 
stiffness improved after soy [52] and whey interventions [53]. However, due to the fact 
that this substudy was powered on energy expenditure, we cannot exclude power issues 
here as well. Literature regarding the relationship of vascular function and endocanna-
binoids is vague and barely investigated in clinical trials. In the current study, vascular 
functional markers did not relate to any of the endocannabinoid measurements. Simi-
larly, OEA and PEA were not related to endothelial function in previous studies [54]. 
However, a connection between the ECS and vascular function cannot be ruled out com-
pletely as PEA was proposed to be a potential biomarker predicting coronary dysfunction 
in morbidly obese patients [54]. 
A limitation of the current study is the investigation of a diet with a higher pro-
tein/carbohydrate ratio compared to a diet with a lower protein/carbohydrate ratio, 
which omits the possibility of a clear separation between effects of an isolated higher 
protein concentration, a lower carbohydrate concentration, or a combination of both. 
In addition, the duration of the substudy was very short which makes a comparison with 
longer-term interventions difficult and we cannot rule out possible effects of the weight-
loss intervention the participants followed before this substudy. Due to the complexity 
of protein quality and other factors of influence, follow-up studies are needed to confirm 
the relevance for ‘normal life’ conditions and to show whether the results can be ex-
trapolated to overweight participants in general. The ECS is an extensive system, includ-
ing different receptors, receptor variants, and ligands [11], that is associated with several 
anthropometric factors such as age and BMI [44,55], which further complicate in-
terpretation of possible effects. 
 
CONCLUSIONS 
In conclusion, our data suggest that a diet with a higher dietary protein content did not 
affect cardiometabolic health and vascular function markers in overweight participants. 
Our data also indicate a possible relation between OEA and PEA and serum lipoprotein 
concentrations, independent of protein intake. Further research is needed to clarify the 
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link between endocannabinoids, their related compounds, and cardiometabolic health 
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Table S4.1: Subject characteristics of the moderate- and high-protein group prior to the respiration 
chamber stay 
Values are means ± SD. BMI = Body Mass Index.  
 
Table S4.2: Office blood pressure at pre- and post-respiration chamber time points with a moderate- 
or high-protein diet 
 Moderate protein 
(n = 18) 
High protein 
(n = 20) 
Treatment 
effect 
 Pre1 Post1 Pre1 Post1 Difference in 
change2 
Brachial SBP (mmHg) 126±10 127±10 130±11 127±12 -2 [-8; 3] 
Brachial DBP (mmHg) 77±7 77±6 78±6 76±7 -2 [-5; 2] 
Brachial MAP (mmHg) 93±7 93±6 95±7 93±8 -2 [-5; 2] 
Brachial PP (mmHg) 49±7 50±10 52±10 51±9 -1 [-5; 4] 
HR (bpm) 62±9 57±6 65±7 62±6 3 [0; 6] 
1Values are means ± SDs. 2 treatment effects [95% CI] were obtained from a one-factor ANCOVA with 
baseline value as covariate. BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood 





Moderate protein High protein 
N (f/m)  18 (9/9) 20 (13/7) 
Age (year) 65.1 ± 5.8 64.0 ± 6.2 
BMI (kg/m2) 29.0 ± 3.8 28.9 ± 4.0 
Body-fat (%) 39.5 ± 8.1 40.7 ± 7.7 
Fat mass (kg) 33.9 ± 7.1 34.8 ± 8.8 
Fat-free mass (kg) 52.5 ± 10.9 50.8 ± 11.3 
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The main objective of this dissertation was to investigate the effects of dietary 
interventions with a mixed high-protein content or soy nuts on several metabolic health 
and vascular function markers in adults. This thesis support previous findings that a 
higher dietary protein intake lowers hunger perception and provides novel insights for 
the involvement of the endocannabinoid-system in energy-intake regulation. The impact 
of 2-arachidonoylglycerol (2-AG) concentrations in protein-related appetite regulation 
might be of great interest for future research as it appeared to be a contributor to the 
appetite-modulating effects in our study. However, the protein intervention or the 
endocannabinoid-system had no impact on cardiometabolic health and vascular 
function markers in our study. In contrast, soy nut consumption improved endothelial 
function and lipoprotein concentrations and therefore lowered cardio-vascular disease 
(CVD) risk in older adults. As the worlds' population, the proportion of the elderly, and 
also the diabetes incidence are expected to further increase in the coming years, it is 
crucial to find strategies to lower the risk for developing non-communicable diseases [1-
3]. This thesis's potential impact in terms of scientific, societal and economic relevance, 
and implications for the translation into practice will be discussed in the following 
paragraphs. 
Societal relevance 
Malnutrition, caused by a diet providing too many or too few nutrients, represents a 
global threat to human health and can result in overweight and obesity or under-
nutrition [4]. Worldwide, the consumption of unhealthy diets with, amongst others, high 
amounts of red meat increases and has been related to an estimation of 990 000 deaths 
in 2017 [5]. Globally, the prevalence of obesity is rapidly increasing and as it is one of the 
main modifiable risk factors for non-communicable diseases, those numbers are 
expected to concurrently increase. Diabetes incidence is enormously growing from a 
prevalence of 4.7% in adults in 1980 to 8.5% in 2014 and caused 1.6 million deaths in 
2016. Approximately 90% of all diabetes cases are assigned to type 2 diabetes mellitus 
(T2DM), which is mostly associated with overweight and unhealthy lifestyle. Therefore, 
lifestyle improvements, such as improvements in body weight, physical activity, and a 
healthy diet, are useful tools in preventing disease development [1]. Even if there are 
several ways to reduce body weight successfully, weight maintenance after weight loss 
remains exceptionally challenging due to activated biological responses to prevent 
further weight loss, amongst other causes. Therefore, it is crucial to find strategies to 
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improve and simplify body weight maintenance to increase the chances of successful 
weight management and lower disease risk. In this context, the high-protein diet of the 
PREVIEW study showed promising results concerning weight management and 
metabolic parameters [6]. Additionally, this thesis shows that an altered hunger 
perception possibly contributed to these beneficial effects and weight management 
improvement. 
Next to promoting T2DM development, obesity strongly relates to the development of 
CVD risk factors, such as hypertension and dyslipidemia [7]. CVD is the most common 
cause of death worldwide, leading to an estimated 17.9 million deaths annually [2]. As 
most CVD are caused by modifiable risk factors, such as an unhealthy diet and obesity, 
powerful prevention strategies could immensely reduce the burden of CVD. In one of 
our studies, we found that the addition of soy nuts to a healthy diet improved various 
risk factors for CVD development, such as an improvement in endothelial function, blood 
pressure, and the lipid profile. The effect on endothelial function, for example, can be 
associated with an overall 12% decreased CV event risk [8].  
Another important risk factor for the above-mentioned non-communicable diseases is 
aging. In the last years, the aging pace of the world's population is increasing. Due to 
enhanced longevity worldwide, the proportion of the elderly is increasing. According to 
the WHO, the population of 60+ years is expected to increase from 12% to 22% between 
2015 and 2050 [3]. Aging is associated with an increased risk of disease development, 
e.g., T2DM due to gradual cellular damage, meaning that a further increase in disease 
incidence can be expected in the coming years. However, healthy aging can, at least 
partly, be promoted by improving behavior and the environment at younger age already. 
This can be done by behavioral changes such as regularly eating a healthy, balanced diet 
and being physically active [3]. Therefore, it is of enormous importance to understand 
the aging process in more detail and find optimal strategies to promote healthy aging at 
the early onset to prevent the development of non-communicable diseases [3]. Multiple 
organ systems and influencing factors are involved in many age-related conditions. 
Those conditions often have shared co-morbidities, indicating underlying mutual causes 
which simultaneously implies the possibility of shared solutions. 
According to the soy study in the current thesis, promising cardiovascular effects in 
persons aged 60 - 70 years has been shown when soy nuts were added on top of a 
healthy diet compared to the healthy diet without any soy product, suggesting that the 
simple addition of soy nuts to the diet may promote healthy aging. In this study, multiple 
possible working mechanisms were analyzed to understand in more detail why the 
consumption of plant-based foods beneficially affects health. 




Due to the highly increasing numbers of CVD and diabetes patients, health care costs 
are increasing accordingly and are expected to rise even higher in the future. The 
diabetes-related costs increase to USD 760 billion in 2019 and have been estimated to 
increase to USD 825 billion in 2030 [9]. While the global CVD-related costs added up to 
USD 863 billion in 2010, they are expected to rise to USD 1044 billion in 2030 [10]. 
Stimulating a healthier lifestyle and a healthier body weight by using dietary intervention 
strategies as described in the current thesis can lower the disease development risk and 
thereby reduce the economic burden of non-communicable diseases. A healthier diet, 
e.g., with more plant-based proteins, could stimulate a healthier aging process and lower 
the need for medical treatments while being relatively cheap and easily accessible for 
many people. It, therefore, contains the possibility of a substantial economic relevance 
by lowering the health care costs of non-communicable diseases in the aging population 
significantly. 
Environmental relevance 
Globally, more than 820 million people have insufficient access to food and even more 
are regularly consuming an unhealthy diet, contributing to a high food-related morbidity 
[11]. Currently, 462 million adults are underweight, another form of malnutrition. This 
number will even increase when no changes in the food production systems are made, 
as the world's population is further increasing to an expected population of around 10 
billion people by 2050 [4,11]. It has been proposed that around 70 - 100% more foods 
will be required in 2050 than produced now [12]. Several adaptions are necessary to 
feed the increasing world's population within the planetary boundaries, such as a change 
to more sustainable agricultural systems. Additionally, the change to a less resource-
intensive diet by reducing animal-based products and including more protein-rich plant-
products instead, such as pulses and soybeans, may help to manage the increasing need 
for food supply in the future [13].  
A shift towards a predominantly plant-based diet combined with improved food 
production and a reduction in food waste is necessary to provide a healthy diet, in 
particular for a growing world population. For both, human and planetary health, a shift 
from animal products to plant-based diets is vital as those diets need fewer resources 
for their production and are therefore more sustainable [14]. Especially the dietary 
protein is a huge point of discussion for shifting to those diets. However, with the 
increased use of nuts, soy, and legumes, protein targets can be achieved with a plant-
based diet [11]. Plant-based products rich in protein, such as soy products, have a better 
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nutrient profile-low climate index than animal-protein sources according to the 
sustainable nutrient-rich food index [15]. It has been shown that water use increases 
with the amount of animal protein in the diet. Furthermore, around two-thirds of 
agricultural and one-third of arable land are currently used for livestock farming. When 
compared to the production of 1 kg rice or potatoes, 1 kg of beef production uses 
approximately 18 times more water and 163 times more land. Additionally, the CO2eq 
production can be reduced by 53% with an entirely plant-based diet compared with a 
typical US diet [16]. 
Target groups 
Both studies presented in this thesis were performed in adults and older adults. While 
the first study with a high-protein diet was completed in pre-diabetic, overweight and 
obese adults, the soy nut study was performed in persons aged 60 to 70 years with a 
normal to overweight BMI and no signs of impaired glucose tolerance or CVD. Multidi-
mensional solutions are needed to tackle the medical, economic, and psychosocial con-
sequences of a growing aging population indicating the special need for studies in the 
elderly to find effective, evidence-based dietary intervention strategies. However, to 
translate those results to a broader population, e.g., young adults or patients with 
established CVD, more research is needed. Next to the scientific impact for patients, the 
outcomes of these studies are also interesting for the food industry to launch healthy, 
evidence-based food concepts for e.g., plant-based products. 
Translation into practice 
Clinical studies in humans are critical for translating findings from cell or animal studies 
to a real-life setting in participants. The protein intervention investigated in this 
dissertation has already been used for an extended period during the PREVIEW study 
[17]. Following the high-protein intervention over three years turned out to be difficult, 
but the dietary intervention still successfully reduced T2DM risk. In contrast, the soy 
study's compliance was excellent, indicating that merely adding a product to the diet 
may be easier to follow over a more extended period. Additionally, this study showed 
beneficial effects of soy nuts despite a healthy diet, possibly pointing out the benefit of 
shifting the diet to a more plant-based origin. The soy nuts provided in this study were 
well tolerated, no serious adverse events occurred, and body weight remained stable 
even when simply adding the product to the regular diet. The daily amount of soy nuts 
was relatively high but feasible for the study period. For a more extended period, 
however, it might be an option to incorporate other soy products to promote this 
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intervention's long-term feasibility and success. Next to the effects on CVD risk, the role 
of plant-based foods in the prevention of other age-related conditions should get much 
more attention in future research. 
This dissertation's results are or will be published in peer-reviewed scientific journals 
and have been presented at scientific conferences to increase awareness of this topic, 
share knowledge, and stimulate further research. These results may be used in a general 
population's advice to promote healthy dietary choices of individuals. Different patient 
organizations or societies could help to inform and provide awareness within specific 
population groups. During both studies, regular dietary guidance for the participants was 
provided to stimulate and promote compliance to the intervention. We strongly suggest 
to include dietary guidance into practice to stimulate a balanced and healthy diet and 
high success rate. 
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Metabolic health and  vascular  function in  adults:  Effects of  a high-protein  diet  and 
soy nuts 
The prevalence of overweight and obesity is rapidly increasing. In 2016, 39% of the 
world’s population was overweight and 13% was obese. Excess body weight is one of 
the leading risk factors for the development of non-communicable diseases, such as type 
II diabetes mellitus and cardiovascular disease (CVD). CVD comprises multiple disorders 
related to heart and blood vessel-related issues and is the leading cause of mortality 
worldwide, with 17.9 million deaths each year. Typical risk factors for the development 
of CVD are cardiometabolic factors such as hypertension and hyper-lipidemia, and 
vascular function markers such as arterial stiffness and endothelial dysfunction.  
Approximately 70% of all CVD can be related to modifiable risk factors. Therefore, 
maintaining a healthy diet and lifestyle is a cornerstone in the prevention of non-
communicable disease due to beneficial effects on risk markers of metabolic and 
vascular health and improved weight management. Here, the diets’ protein content may 
be important, especially for the control of body weight. High-protein diets have been 
suggested to promote satiety via multiple mechanisms. However, not only the total 
amount of protein is of importance, but also the quality and source of protein. Indeed, 
whether it originates from animal or plant sources seems to be an influencing factor in 
preventing or managing these non-communicable diseases. Plant-based diets, for 
example, have been associated with a CVD risk reduction in large cohort studies. An 
essential part of plant-based diets are soy products, as they are a good source of, e.g., 
high-quality plant proteins, polyunsaturated fatty acids, and bioactive compounds such 
as isoflavones.  
This thesis aimed to investigate the effects of a high-protein diet and soy nuts on several 
markers of metabolic health and vascular function in adults.  
Chapters 2 to 4 describe the results of a parallel human intervention trial investigating 
the effects of a mixed high-protein diet on several aspects of food intake regulation, 
endocannabinoids, and cardiometabolic and vascular risk factors in pre-diabetic, over-
weight, or obese participants after completing three years of protein intervention. This 
trial was a substudy of the PREVIEW-trial (Prevention of Diabetes through Lifestyle 
Intervention and Population Studies in Europe and around the World), performed in 
respiration chambers at the Metabolic Research Unit at Maastricht University, allowing 
markedly close monitoring and control. For this, 38 men and women were recruited 
from the PREVIEW study, of which 18 participants consumed the moderate-protein (MP; 
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15/55/30 % energy from protein/carbohydrate/fat) control diet and 20 consumed the 
high-protein diet (HP; 25/45/30 % energy from protein/carbohydrate/fat). During the 
substudy, meals were provided in energy balance. The participants were measured for 
48h in the respiration chamber after approximately 34 months of weight maintenance 
following an eight-week weight reduction period.   
In Chapter 2, the effect of a high-protein diet on appetite regulation has been 
investigated. For this, appetite perception has been assessed with questionnaires and 
metabolic appetite regulation by analyzing anorexigenic hormones (GLP-1 and PYY). 
Participants from the high-protein diet group felt less hungry than those from the 
control group (decremental AUC -56.6%). GLP-1 and PYY concentrations were not 
affected by the dietary protein content, but hunger was inversely associated with the 
PYY concentrations in the HP group only. However, the effect on appetite perception did 
not affect ad libitum energy intake at the end of the study. In the same trial, the role of 
endocannabinoids in energy balance regulation has been assessed. We showed that 2-
arachidonoylglycerol (2-AG) concentrations followed a meal-related pattern with the 
highest concentrations 60 min after the meals. Additionally, concentrations were 
generally higher in the high-protein group. Therefore, 2-AG has been suggested as a 
possible mediator in protein-mediated appetite-regulating effects (Chapter 2). However, 
plasma concentrations of the endocannabinoid anandamide (AEA) and the 
endocannabinoid-related compounds (oleoylethanolamide (OEA), palmitoylethanol-
amide (PEA), and pregnenolone (PREG)) were not affected by the dietary protein 
content as shown in Chapter 3. However, AEA, OEA, PEA, and PREG significantly 
decreased during the day and reflected gradual energy intake matching energy 
expenditure. The decrease in OEA and PEA during the day was inversely associated with 
body mass index and body fat percentage.  
While Chapters 2 and 3 focus mainly on the metabolic components and regulation of 
energy intake, Chapters 4 and 5 describe the effect on cardiometabolic and vascular 
health parameters of two different intervention trials. Chapter 4 reports the impact of 
the high-protein diet, used in the previous chapters, on cardiometabolic and vascular 
risk markers. No effects were found on cardiometabolic markers, such as blood pressure 
and serum lipoprotein concentrations, and vascular function markers, such as endo-
thelial function, arterial stiffness, and microvascular structure. When correlating these 
results with the endocannabinoid concentrations, OEA and PEA were positively asso-
ciated with total (TC) and low-density lipoprotein (LDL) cholesterol concentrations 
suggesting a possible role of the endocannabinoid system in the regulation of hyper-
lipidemia. 
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Chapter 5 describes the results of a longer-term randomized cross-over trial investigat-
ing the effects of soy nut consumption on cardiometabolic and vascular health markers 
in healthy, older adults (60 to 70 years, with a BMI between 20 and 30 kg/m2. Twenty-
three participants consumed 67 g of soy nuts daily on top of a healthy diet or no soy 
products in a randomized order for 16 weeks each. The healthy diet was based on the 
Dutch dietary guidelines. After soy consumption, we found an improved endothelial 
function, office blood pressure, and serum LDL-cholesterol concentrations compared 
with the control condition. Endothelial function, as assessed by brachial artery flow-
mediated vasodilation (FMD) response, improved by 1.49 percentage points (pp), which 
is related to a reduced cardiovascular risk of about 12%. In addition, soy consumption 
improved office blood pressure levels (SBP: -4 mmHg and DBP: -2 mmHg) and the mean 
arterial pressure (-3 mmHg), while LDL-cholesterol concentrations were reduced by 0.17 
mmol/l. Arterial stiffness was unaffected. We concluded from this trial that a longer-
term daily intake of soy improved vascular function and cardiometabolic risk markers in 
older adults, which may contribute to the beneficial effects of plant-based diets on the 
risk of developing CVD. 
In conclusion, based on two human intervention trials, this dissertation provides further 
evidence that dietary protein may play a role in the prevention of non-communicable 
diseases. While a high-protein diet has been shown to affect appetite perception, 
possibly mediated by increased 2-AG and PYY concentrations, no effects were found on 
cardiometabolic or vascular health parameters. Furthermore, longer-term daily intake 
of soy nuts improved endothelial function, blood pressure, and serum LDL-cholesterol 


















Metabole gezondheid en vasculaire functie in volwassenen: Effecten van een eiwitrijke 
voeding en sojanoten 
De prevalentie van overgewicht en obesitas neemt toe. In 2016 had 39% van de 
wereldpopulatie overgewicht en 13% obesitas. Een te hoog lichaamsgewicht is één van 
de belangrijkste risicofactoren voor het ontwikkelen van chronische niet-overdraagbare 
ziekten, zoals diabetes mellitus type 2 (suikerziekte) en hart- en vaatziekten (HVZ). HVZ 
is een verzamelnaam voor een groot aantal aandoeningen van het hart en de bloed-
vaten. Deze aandoeningen zijn de hoofdoorzaak van sterfte en leiden jaarlijks tot meer 
dan 17.9 miljoen overlijdens. Belangrijke risicomarkers voor het ontwikkelen van HVZ 
zijn een verhoogde bloeddruk en ongunstige waarden van metabole risicomarkers, zoals 
het serumcholesterolgehalte, het plasmaglucosegehalte en non-invasieve vaatfunctie-
markers, zoals de endotheelfunctie (vasculaire endotheelfunctie) en stijfheid van de 
bloedvaten (arteriële stijfheid).  
Risicofactoren, die kunnen worden beïnvloed, spelen een belangrijke rol bij de preventie 
van HVZ. Zo heeft een gezonde leefstijl gunstige effecten op de metabole gezondheid 
en vasculaire functie, en op het lichaamsgewicht. Het is bekend dat het eiwitgehalte in 
de voeding hierbij een belangrijke rol speelt, onder andere doordat het bijdraagt tot het 
in stand houden van een gezond lichaamsgewicht. Uit eerder onderzoek is bijvoorbeeld 
gebleken dat een eiwitrijke voeding verzadigend werkt. Niet alleen de totale hoeveel-
heid eiwit in de voeding is hierbij van belang, maar ook de kwaliteit en de bron van de 
eiwitten. Voor het voorkomen van chronische ziekten is het mogelijk ook belangrijk of 
het eiwit afkomstig is van dieren of planten. Zo is een voeding rijk aan plantaardige 
producten geassocieerd met een verlaagd risico op HVZ. Een belangrijk onderdeel van 
een plantaardige voeding zijn bijvoorbeeld sojaproducten omdat soja een bron is van 
hoogwaardige eiwitten, meervoudig onverzadigde vetzuren en bioactieve stoffen, zoals 
isoflavonen.  
Het doel van dit proefschrift was nu om de effecten te onderzoeken van zowel een 
eiwitrijke voeding als sojanoten op verschillende markers voor metabole gezondheid en 
vasculaire functie in volwassenen.  
In hoofdstuk 2, 3 en 4 zijn de resultaten van een humane interventiestudie beschreven. 
In deze studie zijn de effecten onderzocht van een eiwitrijke voeding afkomstig van 
zowel dierlijke als plantaardige producten op verschillende aspecten van de regulatie 
van de voedingsinname, endocannabinoïde concentraties, en cardiometabole en 
vasculaire risicofactoren. Hiervoor is gebruik gemaakt van een driejarige voedings-
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interventiestudie in vrijwilligers met prediabetes en overgewicht of obesitas. Deze studie 
was een deelstudie van de PREVIEW-studie (Prevention of Diabetes through Lifestyle 
Intervention and Population Studies in Europe and around the World) en is uitgevoerd 
in de respiratiekamers van de Metabole Research Unit in Maastricht (MRUM). In totaal 
werden 38 mannen en vrouwen uit de PREVIEW-studie geworven, waarvan 18 
deelnemers de controlevoeding consumeerden met een matig eiwitgehalte (MP; 
15/55/30% energie uit eiwitten/ koolhydraten/ vet) en 20 deelnemers de eiwitrijke 
voeding (HP; 25/45/30% energie uit eiwit/ koolhydraten/ vet). Tijdens de studie waren 
de deelnemers in energiebalans. Na een periode van acht weken afvallen werden 
deelnemers na 34 maanden gedurende 48 uur in de respiratiekamer gemeten onder 
zeer gecontroleerde omstandigheden.  
In hoofdstuk 2 werd het effect van een eiwitrijke voeding op de regulatie van de eetlust 
onderzocht. Hiervoor is de perceptie van eetlust beoordeeld door middel van vragen-
lijsten en de concentraties van de verzadigende hormonen GLP-1 en PYY gemeten. 
Deelnemers in de eiwitrijke voedingsgroep hadden een minder grote eetlust dan de 
deelnemers in de controlegroep. Concentraties van de hormonen GLP-1 en PYY werden 
niet beïnvloed door het eiwitgehalte in de voeding, maar het hongergevoel was wel 
omgekeerd geassocieerd met de PYY-concentraties in de eiwitrijke groep. Het effect op 
de hongerperceptie had echter geen invloed op de ad libitum energie-inname aan het 
einde van de studie. Verder hebben we in dezelfde studie de rol van endocannabinoïden 
onderzocht met betrekking tot de regulatie van de energiebalans. We hebben aan-
getoond dat de concentraties van 2-arachidonoylglycerol (2-AG) een maaltijd-
gerelateerd patroon volgden, waarbij de hoogste concentraties werden waargenomen 
60 minuten na de maaltijden. Bovendien waren de concentraties over het algemeen 
hoger in de eiwitrijke groep. Daarom werd 2-AG voorgesteld als een mogelijke mediator 
van de eiwit-gemedieerde eetlust-regulerende effecten (Hoofdstuk 2). Zoals weer-
gegeven in hoofdstuk 3 werden concentraties van de endocannabinoïde anandamide 
(AEA) en de endocannabinoïd-gerelateerde verbindingen (oleoylethanolamide (OEA), 
palmitoylethanolamide (PEA) en pregnenolon (PREG)) niet beïnvloed door het 
eiwitgehalte in de voeding. AEA, OEA, PEA en PREG namen significant af gedurende de 
dag en weerspiegelden de geleidelijke energie-inname, die overeenkwam met het 
energieverbruik. De afname van OEA en PEA gedurende de dag was omgekeerd 
geassocieerd met de BMI en het percentage lichaamsvet. 
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Hoofdstuk 2 en 3 beschrijven de metabole parameters en regulatie van de energie-
inname, terwijl in hoofdstuk 4 en 5 de effecten op de cardiometabole en vasculaire 
gezondheidsparameters worden beschreven die onderzocht zijn in twee verschillende 
interventiestudies. Hoofdstuk 4 beschrijft de specifieke effecten van een eiwitrijke 
voeding. Er werden geen effecten gevonden op cardiometabole risicomarkers, zoals de 
bloeddruk en serum lipoproteïneconcentraties, en de vasculaire functiemarkers, zoals 
vasculaire endotheelfunctie, arteriële stijfheid en markers gerelateerd aan de micro-
circulatie. Wanneer deze resultaten werden gecorreleerd met endocannabinoïde con-
centraties, waren OEA en PEA positief geassocieerd met de totale- en LDL-cholesterol-
concentratie. Dit zou op een mogelijke rol van het endocannabinoïde systeem bij de 
regulering van hyperlipidemie kunnen duiden. 
Hoofdstuk 5 beschrijft de resultaten van een gerandomiseerde cross-over studie naar 
de langetermijneffecten van sojanoten op cardiometabole en vasculaire gezondheids-
markers in gezonde oudere volwassenen (60 tot 70 jaar, met een BMI tussen 20 en 30 
kg/m2). Drieëntwintig deelnemers consumeerden in een willekeurige volgorde 
gedurende 16 weken een voedingspatroon gebaseerd op de Nederlandse richtlijnen 
voor een gezonde voeding. Deze voeding werd wel of niet (controleconditie) aangevuld 
met dagelijks 67 g sojanoten. Na consumptie van de sojanoten vonden we een 
verbetering in de endotheelfunctie, bloeddruk en serum LDL-cholesterol-concentraties 
in vergelijking met de controleconditie. De flow-gemedieerde vasodilatatie van de 
arteria brachialis (FMD) verbeterde met 1.49 procentpunten (pp), hetgeen gerelateerd 
is aan een daling van het risico op HVZ van ongeveer 12%. Bovendien verbeterde na 
sojaconsumptie de systole en diastole bloeddruk (SBP: -4 mmHg en DBP: -2 mmHg), en 
daalde de gemiddelde arteriële druk (-3 mmHg). Serum LDL-cholesterolconcentraties 
namen af met 0.17 mmol/l, maar de polsgolfsnelheid in de aorta (PWV) als maat voor 
de arteriële stijfheid werd niet beïnvloed. Op basis van de resultaten van deze studie 
concludeerden we dat een dagelijkse consumptie van sojanoten de vasculaire functie en 
metabole gezondheid bij oudere volwassenen verbetert. Dit kan bijdragen aan de 
gunstige effecten van een plantaardig voedingspatroon op het risico voor het 
ontwikkelen van HVZ. 
In conclusie, dit proefschrift levert op basis van twee humane interventiestudies verder 
bewijs dat eiwitten in de voeding een rol kunnen spelen bij de preventie van niet-
overdraagbare chronische ziekten, zoals HVZ. Er is aangetoond dat een eiwitrijke 
voeding de perceptie van eetlust beïnvloedt, hetgeen mogelijk gemedieerd wordt door 
verhoogde 2-AG- en PYY-concentraties. Er werden echter geen effecten gevonden op de 
cardiometabole of vasculaire gezondheidsparameters. Een lange-termijnconsumptie 
Samenvatting | APPENDIX 
 163 
van sojanoten verbeterde de endotheelfunctie, de bloeddruk en de serum LDL-
cholesterolconcentraties, hetgeen een mogelijk mechanisme is waardoor soja-








Stoffwechselgesundheit und Funktionalität der Blutgefäße in Erwachsenen: 
Auswirkungen einer proteinreichen Ernährung und Soja-Nüssen 
In den letzten Jahren hat die Prävalenz von Übergewicht und Adipositas stetig 
zugenommen. Im Jahr 2016 waren 39% der Weltbevölkerung übergewichtig und 13% 
waren fettleibig. Übergewicht ist einer der Hauptrisikofaktoren für die Entwicklung 
nichtübertragbarer Erkrankungen wie Diabetes mellitus Typ II und Herz-Kreislauf-
Erkrankungen. Herz-Kreislauf-Erkrankungen umfassen mehrere Syndrome die im 
Zusammenhang mit Herz- und Blutgefäßproblemen stehen und sind mit 17,9 Millionen 
Todesfällen pro Jahr die weltweit häufigste Todesursache. Typische Risikofaktoren für 
die Entwicklung von Herz-Kreislauf-Erkrankungen sind kardiometabolische Faktoren wie 
Bluthochdruck und Hyperlipidämie sowie Veränderungen der Marker für die Funktionali-
tät der Blutgefäße. Dies kann zum Beispiel eine verringerte Gefäßelastizität oder eine 
Dysfunktion des Endotheliums sein. 
Ungefähr 70% aller Herz-Kreislauf-Erkrankungen können mit modifizierbaren Risiko-
faktoren in Zusammenhang gebracht werden. Eine besondere Rolle spielen dabei ein 
gesunde Ernährung und ein gesunder Lebensstils. Dies kann sich positiv auf einige 
Risikomarker für die Stoffwechsel- und Blutgefäßgesundheit und auch auf ein 
verbessertes Gewichtsmanagement auswirken und stellt somit einen wichtigen 
Eckpfeiler bei der Prävention dieser nichtübertragbaren Erkrankungen dar. Ins-
besondere für die Kontrolle des Körpergewichts kann der Eiweißgehalt der Nahrung 
wichtig sein. Eine eiweißreiche Ernährung kann zum Beispiel das Sättigungsgefühl durch 
verschiedene Mechanismen beeinflussen. Möglicherweise ist jedoch nicht nur die 
Gesamtmenge des Eiweißes von Bedeutung, sondern auch die Qualität und der 
Ursprung. Ob es aus tierischen oder pflanzlichen Quellen stammt, scheint einer der 
Einflussfaktoren bei der Vorbeugung oder Behandlung dieser nichtübertragbaren 
Erkrankungen zu sein. Pflanzliche Ernährungsweisen wurden beispielsweise in großen 
Kohortenstudien mit einer Verringerung des Risikos für Herz-Kreislauf-Erkrankungen in 
Verbindung gebracht. Einen wesentlichen Bestandteil pflanzlicher Ernährungsweisen 
stellen Sojaprodukte dar, da sie eine gute Quelle für hochwertige pflanzliche Eiweiße, 
mehrfach ungesättigte Fettsäuren und bioaktive Stoffe wie Isoflavone sind. 
Ziel dieser Doktorarbeit war es, die Auswirkungen einer eiweißreichen Ernährung und 
von Soja-Nüssen auf verschiedene Marker für die Stoffwechselgesundheit und die 
Gefäßfunktion bei Erwachsenen zu untersuchen. 
Zusammenfassung | APPENDIX 
 165 
In den Kapiteln 2 bis 4 werden die Ergebnisse einer parallelen Interventionsstudie bei 
Erwachsenen beschrieben, in der die Auswirkungen einer eiweißreichen, gemischten 
Ernährung auf verschiedene Aspekte der Nahrungsaufnahmeregulation, Endocanna-
binoide, sowie kardiometabolische und vaskuläre Risikofaktoren untersucht. Dies wurde 
in prä-diabetischen, übergewichtigen oder adipösen Teilnehmern im Anschluss an eine 
dreijährige eiweißreiche Ernährungsintervention gemessen. Diese Studie war Teil der 
internationalen PREVIEW-Studie (Prevention of Diabetes through Lifestyle Intervention 
and Population Studies in Europe and around the World), die in den Kalorimeter Räumen 
(respiration chambers) der Metabolic Research Unit der Universität Maastricht 
durchgeführt wurde, was eine sehr genaue Überwachung und Kontrolle der 
Studiensituation ermöglichte. Für diese Teilstudie wurden 38 Männer und Frauen aus 
der PREVIEW-Studie rekrutiert, von denen 18 Teilnehmer die Kontrolldiät mit mäßigem 
Eiweißanteil (MP; 15/ 55/ 30% Energie aus Protein/ Kohlenhydrat/ Fett) und die anderen 
20 Teilnehmer die eiweißreiche Diät konsumierten (HP; 25/ 45/ 30% Energie aus 
Protein/ Kohlenhydraten/ Fett). Während der Teilstudie wurden die Mahlzeiten 
basierend auf dem individuellen Bedarf bereitgestellt. Die Teilnehmer wurden nach 
einer achtwöchigen Gewichtsreduktionsperiode und ungefähr 34 Monaten Gewichts-
erhaltung, 48 Stunden lang in den Kalorimeter Räumen untersucht. 
In Kapitel 2 wurde die Auswirkung einer eiweißreichen Ernährung auf Hunger und 
Sättigung untersucht. Zu diesem Zweck wurde der wahrgenommene Appetit mit 
Fragebögen und die metabolische Regulation des Appetits durch die Analyse von 
sättigenden Hormonen (GLP-1 und PYY) bewertet. Teilnehmer aus der eiweißreichen 
Diätgruppe verspürten weniger Hunger als Teilnehmer aus der Kontrollgruppe 
(dekrementelle AUC -56,6%). Die GLP-1 und PYY-Konzentrationen wurden hingegen 
nicht durch den Eiweißgehalt in der Nahrung beeinflusst, aber das Hungergefühl war 
negativ mit den PYY-Konzentrationen in der HP-Gruppe korreliert. Die Auswirkung auf 
das Hungergefühl hatte jedoch keinen Einfluss auf die Ad-libitum-Energieaufnahme nach 
den 48 Stunden in den Kalorimeter Räumen. In derselben Studie wurde auch die Rolle 
von Endocannabinoid-Konzentrationen bei der Regulation der Energieaufnahme 
untersucht. Wir zeigten, dass die Konzentrationen von 2-Arachidonoylglycerin (2-AG) 
einem mahlzeitbezogenen Muster mit den höchsten Konzentrationen 60 Minuten nach 
den Mahlzeiten folgten. Zusätzlich waren die 2-AG Konzentrationen in der eiweißreichen 
Gruppe im Allgemeinen höher. Daher haben wir 2-AG als einen möglichen Mediator für 
die eiweißvermittelten appetitregulierenden Effekte vorgeschlagen (Kapitel 2). Die 
Plasmakonzentrationen des Endocannabinoids Anandamid (AEA) und der Endo-
cannabinoid-verwandten Verbindungen Oleoylethanolamid (OEA), Palmitoylethanol-
amid (PEA) und Pregnenolon (PREG) wurden jedoch nicht durch den Eiweißgehalt der 
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Nahrung beeinflusst (Kapitel 3). In Kapitel 3 zeigen wir auch, dass AEA, OEA, PEA und 
PREG-Konzentrationen tagsüber signifikant abnehmen und die Energieaufnahme über 
den Tag verteilt schrittweise wiederspiegeln. Die Abnahme von OEA und PEA während 
des Tages war negativ mit dem BMI und dem Körperfettanteil korreliert. 
Während sich die Kapitel 2 und 3 hauptsächlich auf die metabolen Komponenten und 
die Regulation der Energieaufnahme konzentrieren, beschreiben Kapitel 4 und 5 die 
Auswirkungen zweier verschiedener Interventionsstudien auf verschiedene kardio-
metabolische und vaskuläre Gesundheitsparameter. Kapitel 4 zeigt die Auswirkungen 
der eiweißreichen Ernährung, die auch in den vorherigen Kapiteln verwendet wurde, auf 
kardiometabolische und vaskuläre Risikomarker. Sowohl die kardiometabolischen 
Marker wie Blutdruck und Serum Lipoprotein Konzentrationen als auch die Marker für 
die Funktionalität der Gefäße, wie eine verringerte Gefäßelastizität, eine Dysfunktion 
des Endotheliums und die mikrovaskuläre Struktur, waren unverändert. Bei der 
Korrelation dieser Werte mit den Endocannabinoid Konzentrationen waren OEA und 
PEA positiv mit den Gesamtcholesterinkonzentrationen (TC) und dem Lipoprotein 
niedriger Dichte (LDL) assoziiert, was auf eine mögliche Rolle des Endocannabinoid-
Systems bei der Regulation der Hyperlipidämie hinweisen könnte. 
Kapitel 5 beschreibt die Ergebnisse einer längeren randomisierten Cross-Over-Studie, in 
der die Auswirkungen des Konsums von gerösteten Sojabohnen (Soja-Nüsse) auf 
kardiometabolische und vaskuläre Gesundheitsparameter in gesunden älteren 
Erwachsenen (60 bis 70 Jahre mit einem BMI zwischen 20 und 30 kg/m2) untersucht 
wurden. Dreiundzwanzig Teilnehmer konsumierten 67 g Soja-Nüsse täglich, zusätzlich 
zu einer ausgewogenen Ernährung, oder ein kompletter Verzicht auf jegliche Soja-
produkte, in einer zufälligen Reihenfolge für jeweils 16 Wochen. Die ausgewogene 
Ernährung war auf den niederländischen Ernährungsrichtlinien basiert. Nach dem 
Verzehr des Sojaprodukts konnten wir eine verbessertes Funktion des Endothels, des 
manuellen Blutdrucks und der Serum-LDL-Cholesterinkonzentrationen im Vergleich zur 
Kontrollbedingung (ausgewogenen Ernährung ohne Soja) feststellen. Die Endothel-
funktion, bewertet durch die flussvermittelte endothelabhängige Vasodilatation (FMD, 
„flow-mediated dilatation“) verbesserte sich um 1.49 Prozentpunkte (pp), eine Ver-
besserung die mit einer Verringerung des kardiovaskulären Risikos von etwa 12% in 
Zusammenhang gebracht wird. Zusätzlich verbesserte der Soja-Nuss Konsum den 
manuell gemessenen Blutdruck (SBP: -4 mmHg und DBP: -2 mmHg) und den mittleren 
arteriellen Druck (-3 mmHg), während die LDL-Cholesterinkonzentrationen um 0.17 
mmol/l reduziert wurden. Die Gefäßelastizität blieb hingegen unverändert. Aus dieser 
Studie schließen wir, dass eine längerfristige tägliche Einnahme von gerösteten 
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Sojabohnen die Gefäßfunktion und die kardiometabolischen Risikomarker bei älteren 
Erwachsenen verbessert, was zu den positiven Auswirkungen einer pflanzlicher 
Ernährung auf das Risiko der Entwicklung von Herz- und Gefäßerkrankungen beitragen 
kann. 
Zusammenfassend liefert diese Doktorarbeit, auf der Grundlage von zwei Interventions-
studien am Menschen, weitere Beweise dafür, dass eiweißreiche Produkte in der 
Ernährung eine Rolle bei der Prävention nicht übertragbarer Erkrankungen spielen 
können. Während gezeigt wurde, dass eine eiweißreiche Ernährung das Hunger- und 
Sättigungsprofiel beeinflusst, möglicherweise vermittelt durch erhöhte 2-AG und PYY-
Konzentrationen, wurden keine Auswirkungen auf die kardiometabolischen oder 
vaskulären Gesundheitsparameter gefunden. Die längerfristige tägliche Einnahme von 
gerösteten Sojabohnen konnte hingegen die Endothelfunktion, den Blutdruck und die 
LDL-Cholesterinkonzentrationen im Serum verbessern. Diese Parameter stellen gleich-
zeitig mögliche Mechanismen dar, durch die Sojaprodukte letztendlich das Risiko auf die 
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